



107	713	100.0	713	1	US-10-143-032-473	Sequence 473, App	Sequence 473, App	180	713	100.0	713	1	US-10-147-508-473	Sequence 473, App
108	713	100.0	713	1	US-10-123-108-473	Sequence 473, App	Sequence 473, App	181	713	100.0	713	1	US-10-147-512-473	Sequence 473, App
109	713	100.0	713	1	US-10-123-236-473	Sequence 473, App	Sequence 473, App	182	713	100.0	713	1	US-10-175-735-473	Sequence 473, App
110	713	100.0	713	1	US-10-123-261-473	Sequence 473, App	Sequence 473, App	183	713	100.0	713	1	US-10-121-040-473	Sequence 473, App
111	713	100.0	713	1	US-10-140-921-473	Sequence 473, App	Sequence 473, App	184	713	100.0	713	1	US-10-121-056-473	Sequence 473, App
112	713	100.0	713	1	US-10-140-928-473	Sequence 473, App	Sequence 473, App	185	713	100.0	713	1	US-10-121-061-473	Sequence 473, App
113	713	100.0	713	1	US-10-121-045-473	Sequence 473, App	Sequence 473, App	186	713	100.0	713	1	US-10-123-235-473	Sequence 473, App
114	713	100.0	713	1	US-10-123-292-473	Sequence 473, App	Sequence 473, App	187	713	100.0	713	1	US-10-123-235-473	Sequence 473, App
115	713	100.0	713	1	US-10-123-903-473	Sequence 473, App	Sequence 473, App	188	713	100.0	713	1	US-10-124-818-473	Sequence 473, App
116	713	100.0	713	1	US-10-124-819-473	Sequence 473, App	Sequence 473, App	189	713	100.0	713	1	US-10-137-868-473	Sequence 473, App
117	713	100.0	713	1	US-10-124-822-473	Sequence 473, App	Sequence 473, App	190	713	100.0	713	1	US-10-147-492-473	Sequence 473, App
118	713	100.0	713	1	US-10-140-925-473	Sequence 473, App	Sequence 473, App	191	713	100.0	713	1	US-10-158-782-473	Sequence 473, App
119	713	100.0	713	1	US-10-160-498-473	Sequence 473, App	Sequence 473, App	192	713	100.0	713	1	US-10-123-905-473	Sequence 473, App
120	713	100.0	713	1	US-10-124-824-473	Sequence 473, App	Sequence 473, App	193	713	100.0	713	1	US-10-123-907-473	Sequence 473, App
121	713	100.0	713	1	US-10-127-825A-473	Sequence 473, App	Sequence 473, App	194	713	100.0	713	1	US-10-124-815-473	Sequence 473, App
122	713	100.0	713	1	US-10-127-829A-473	Sequence 473, App	Sequence 473, App	195	713	100.0	713	1	US-10-125-921A-473	Sequence 473, App
123	713	100.0	713	1	US-10-127-835A-473	Sequence 473, App	Sequence 473, App	196	713	100.0	713	1	US-10-125-928A-473	Sequence 473, App
124	713	100.0	713	1	US-10-127-839A-473	Sequence 473, App	Sequence 473, App	197	713	100.0	713	1	US-10-127-821A-473	Sequence 473, App
125	713	100.0	713	1	US-10-127-901A-473	Sequence 473, App	Sequence 473, App	198	713	100.0	713	1	US-10-127-822A-473	Sequence 473, App
126	713	100.0	713	1	US-10-128-693A-473	Sequence 473, App	Sequence 473, App	199	713	100.0	713	1	US-10-127-824A-473	Sequence 473, App
127	713	100.0	713	1	US-10-131-813A-473	Sequence 473, App	Sequence 473, App	200	713	100.0	713	1	US-10-127-826A-473	Sequence 473, App
128	713	100.0	713	1	US-10-131-818A-473	Sequence 473, App	Sequence 473, App	201	713	100.0	713	1	US-10-127-827A-473	Sequence 473, App
129	713	100.0	713	1	US-10-131-823A-473	Sequence 473, App	Sequence 473, App	202	713	100.0	713	1	US-10-127-828A-473	Sequence 473, App
130	713	100.0	713	1	US-10-131-824A-473	Sequence 473, App	Sequence 473, App	203	713	100.0	713	1	US-10-127-830A-473	Sequence 473, App
131	713	100.0	713	1	US-10-131-830A-473	Sequence 473, App	Sequence 473, App	204	713	100.0	713	1	US-10-127-832A-473	Sequence 473, App
132	713	100.0	713	1	US-10-131-837A-473	Sequence 473, App	Sequence 473, App	205	713	100.0	713	1	US-10-127-833A-473	Sequence 473, App
133	713	100.0	713	1	US-10-137-872A-473	Sequence 473, App	Sequence 473, App	206	713	100.0	713	1	US-10-127-834A-473	Sequence 473, App
134	713	100.0	713	1	US-10-147-500-473	Sequence 473, App	Sequence 473, App	207	713	100.0	713	1	US-10-127-836A-473	Sequence 473, App
135	713	100.0	713	1	US-10-147-502-473	Sequence 473, App	Sequence 473, App	208	713	100.0	713	1	US-10-127-841A-473	Sequence 473, App
136	713	100.0	713	1	US-10-147-515-473	Sequence 473, App	Sequence 473, App	209	713	100.0	713	1	US-10-128-687A-473	Sequence 473, App
137	713	100.0	713	1	US-10-147-517-473	Sequence 473, App	Sequence 473, App	210	713	100.0	713	1	US-10-128-688A-473	Sequence 473, App
138	713	100.0	713	1	US-10-147-526-473	Sequence 473, App	Sequence 473, App	211	713	100.0	713	1	US-10-128-689A-473	Sequence 473, App
139	713	100.0	713	1	US-10-147-527-473	Sequence 473, App	Sequence 473, App	212	713	100.0	713	1	US-10-128-694A-473	Sequence 473, App
140	713	100.0	713	1	US-10-121-041-473	Sequence 473, App	Sequence 473, App	213	713	100.0	713	1	US-10-131-825A-473	Sequence 473, App
141	713	100.0	713	1	US-10-121-043-473	Sequence 473, App	Sequence 473, App	214	713	100.0	713	1	US-10-230-417-473	Sequence 473, App
142	713	100.0	713	1	US-10-121-047-473	Sequence 473, App	Sequence 473, App	215	713	100.0	713	1	US-10-131-815A-473	Sequence 473, App
143	713	100.0	713	1	US-10-123-215-473	Sequence 473, App	Sequence 473, App	216	713	100.0	713	1	US-10-131-817A-473	Sequence 473, App
144	713	100.0	713	1	US-10-123-215-473	Sequence 473, App	Sequence 473, App	217	713	100.0	713	1	US-10-131-821A-473	Sequence 473, App
145	713	100.0	713	1	US-10-123-908-473	Sequence 473, App	Sequence 473, App	218	713	100.0	713	1	US-10-131-822A-473	Sequence 473, App
146	713	100.0	713	1	US-10-123-909-473	Sequence 473, App	Sequence 473, App	219	713	100.0	713	1	US-10-131-828A-473	Sequence 473, App
147	713	100.0	713	1	US-10-123-910-473	Sequence 473, App	Sequence 473, App	220	713	100.0	713	1	US-10-131-835A-473	Sequence 473, App
148	713	100.0	713	1	US-10-124-813-473	Sequence 473, App	Sequence 473, App	221	713	100.0	713	1	US-10-137-864A-473	Sequence 473, App
149	713	100.0	713	1	US-10-124-817-473	Sequence 473, App	Sequence 473, App	222	713	100.0	713	1	US-10-137-869A-473	Sequence 473, App
150	713	100.0	713	1	US-10-125-922-473	Sequence 473, App	Sequence 473, App	223	713	100.0	713	1	US-10-147-523-473	Sequence 473, App
151	713	100.0	713	1	US-10-125-924-473	Sequence 473, App	Sequence 473, App	224	713	100.0	713	1	US-10-158-785-473	Sequence 473, App
152	713	100.0	713	1	US-10-125-924-473	Sequence 473, App	Sequence 473, App	225	713	100.0	713	1	US-10-121-051-473	Sequence 473, App
153	713	100.0	713	1	US-10-140-860-473	Sequence 473, App	Sequence 473, App	226	713	100.0	713	1	US-10-121-042-473	Sequence 473, App
154	713	100.0	713	1	US-10-142-417-473	Sequence 473, App	Sequence 473, App	227	713	100.0	713	1	US-10-123-913-473	Sequence 473, App
155	713	100.0	713	1	US-10-147-519-473	Sequence 473, App	Sequence 473, App	228	713	100.0	713	1	US-10-192-007-473	Sequence 473, App
156	713	100.0	713	1	US-10-157-782-473	Sequence 473, App	Sequence 473, App	229	713	100.0	713	1	US-10-194-359-473	Sequence 473, App
157	713	100.0	713	1	US-10-152-395-473	Sequence 473, App	Sequence 473, App	230	713	100.0	713	1	US-10-127-847A-473	Sequence 473, App
158	713	100.0	713	1	US-10-125-926A-473	Sequence 473, App	Sequence 473, App	231	713	100.0	713	1	US-10-175-590-473	Sequence 473, App
159	713	100.0	713	1	US-10-125-930A-473	Sequence 473, App	Sequence 473, App	232	713	100.0	713	1	US-10-137-866-473	Sequence 473, App
160	713	100.0	713	1	US-10-127-831A-473	Sequence 473, App	Sequence 473, App	233	713	100.0	713	1	US-10-146-726-473	Sequence 473, App
161	713	100.0	713	1	US-10-127-837A-473	Sequence 473, App	Sequence 473, App	234	713	100.0	713	1	US-10-146-727-473	Sequence 473, App
162	713	100.0	713	1	US-10-127-838B-473	Sequence 473, App	Sequence 473, App	235	713	100.0	713	1	US-10-146-788-473	Sequence 473, App
163	713	100.0	713	1	US-10-127-842A-473	Sequence 473, App	Sequence 473, App	236	713	100.0	713	1	US-10-152-380-473	Sequence 473, App
164	713	100.0	713	1	US-10-127-843A-473	Sequence 473, App	Sequence 473, App	237	713	100.0	713	1	US-10-153-934-473	Sequence 473, App
165	713	100.0	713	1	US-10-127-845A-473	Sequence 473, App	Sequence 473, App	238	713	100.0	713	1	US-10-140-807-473	Sequence 473, App
166	713	100.0	713	1	US-10-127-846A-473	Sequence 473, App	Sequence 473, App	239	713	100.0	713	1	US-10-140-924-473	Sequence 473, App
167	713	100.0	713	1	US-10-127-848A-473	Sequence 473, App	Sequence 473, App	240	713	100.0	713	1	US-10-140-926-473	Sequence 473, App
168	713	100.0	713	1	US-10-127-849A-473	Sequence 473, App	Sequence 473, App	241	713	100.0	713	1	US-10-141-698-473	Sequence 473, App
169	713	100.0	713	1	US-10-127-851A-473	Sequence 473, App	Sequence 473, App	242	713	100.0	713	1	US-10-141-702-473	Sequence 473, App
170	713	100.0	713	1	US-10-128-684A-473	Sequence 473, App	Sequence 473, App	243	713	100.0	713	1	US-10-141-704-473	Sequence 473, App
171	713	100.0	713	1	US-10-128-686A-473	Sequence 473, App	Sequence 473, App	244	713	100.0	713	1	US-10-142-421-473	Sequence 473, App
172	713	100.0	713	1	US-10-128-690A-473	Sequence 473, App	Sequence 473, App	245	713	100.0	713	1	US-10-142-432-473	Sequence 473, App
173	713	100.0	713	1	US-10-128-691A-473	Sequence 473, App	Sequence 473, App	246	713	100.0	713	1	US-10-143-767-473	Sequence 473, App
174	713	100.0	713	1	US-10-131-819A-473	Sequence 473, App	Sequence 473, App	247	713	100.0	713	1	US-10-143-033-473	Sequence 473, App
175	713	100.0	713	1	US-10-131-829A-473	Sequence 473, App	Sequence 473, App	248	713	100.0	713	1	US-10-144-994-473	Sequence 473, App
176	713	100.0	713	1	US-10-131-836A-473	Sequence 473, App	Sequence 473, App	249	713	100.0	713	1	US-10-145-628-473	Sequence 473, App
177	713	100.0	713	1	US-10-146-729-473	Sequence 473, App	Sequence 473, App	250	713	100.0	713	1	US-10-145-746-473	Sequence 473, App
178	713	100.0	713	1	US-10-146-791-473	Sequence 473, App	Sequence 473, App	251	713	100.0	713	1	US-10-145-748-473	Sequence 473, App
179	713	100.0	713	1	US-10-147-484-473	Sequence 473, App	Sequence 473, App	252	713	100.0	713	1	US-10-145-823-473	Sequence 473, App

[illegible]

399 713 100.0 713 1 US-10-123-157-473 Sequence 473, App  
400 713 100.0 713 1 US-10-123-306-473 Sequence 473, App  
401 713 100.0 713 1 US-10-124-814-473 Sequence 473, App  
402 713 100.0 713 1 US-10-124-816-473 Sequence 473, App  
403 713 100.0 713 1 US-10-124-820-473 Sequence 473, App  
404 713 100.0 713 1 US-10-125-704-473 Sequence 473, App  
405 713 100.0 713 1 US-10-125-727-473 Sequence 473, App  
406 713 100.0 713 1 US-10-142-889-473 Sequence 473, App  
407 713 100.0 713 1 US-10-145-874-473 Sequence 473, App  
408 713 100.0 713 1 US-10-147-497-473 Sequence 473, App  
409 713 100.0 713 1 US-10-152-371-473 Sequence 473, App  
410 713 100.0 713 1 US-10-152-374-473 Sequence 473, App  
411 713 100.0 713 1 US-10-152-375-473 Sequence 473, App  
412 713 100.0 713 1 US-10-152-377-473 Sequence 473, App  
413 713 100.0 713 1 US-10-152-386-473 Sequence 473, App  
414 713 100.0 713 1 US-10-152-391-473 Sequence 473, App  
415 713 100.0 713 1 US-10-152-399-473 Sequence 473, App  
416 713 100.0 713 1 US-10-156-848-473 Sequence 473, App  
417 713 100.0 713 1 US-10-157-785-473 Sequence 473, App  
418 713 100.0 713 1 US-10-157-794-473 Sequence 473, App  
419 713 100.0 713 1 US-10-157-796-473 Sequence 473, App  
420 713 100.0 713 1 US-10-160-500-473 Sequence 473, App  
421 713 100.0 713 1 US-10-121-046-473 Sequence 473, App  
422 713 100.0 713 1 US-10-123-156-473 Sequence 473, App  
423 713 100.0 713 1 US-10-123-214-473 Sequence 473, App  
424 713 100.0 713 1 US-10-125-805-473 Sequence 473, App  
425 713 100.0 713 1 US-10-124-821-473 Sequence 473, App  
426 713 100.0 713 1 US-10-152-385-473 Sequence 473, App  
427 713 100.0 713 1 US-10-152-393-473 Sequence 473, App  
428 713 100.0 713 1 US-10-152-396-473 Sequence 473, App  
429 713 100.0 713 1 US-10-153-552-473 Sequence 473, App  
430 713 100.0 713 1 US-10-153-840-473 Sequence 473, App  
431 713 100.0 713 1 US-10-156-841-473 Sequence 473, App  
432 713 100.0 713 1 US-10-156-842-473 Sequence 473, App  
433 713 100.0 713 1 US-10-156-844-473 Sequence 473, App  
434 713 100.0 713 1 US-10-156-845-473 Sequence 473, App  
435 713 100.0 713 1 US-10-156-846-473 Sequence 473, App  
436 713 100.0 713 1 US-10-121-048-473 Sequence 473, App  
437 713 100.0 713 1 US-10-121-052-473 Sequence 473, App  
438 713 100.0 713 1 US-10-121-053-473 Sequence 473, App  
439 713 100.0 713 1 US-10-121-054-473 Sequence 473, App  
440 713 100.0 713 1 US-10-121-063-473 Sequence 473, App  
441 713 100.0 713 1 US-10-123-212-473 Sequence 473, App  
442 713 100.0 713 1 US-10-123-213-473 Sequence 473, App  
443 713 100.0 713 1 US-10-123-291-473 Sequence 473, App  
444 713 100.0 713 1 US-10-123-322-473 Sequence 473, App  
445 713 100.0 713 1 US-10-123-771-473 Sequence 473, App  
446 713 100.0 713 1 US-10-123-911-473 Sequence 473, App  
447 713 100.0 713 1 US-10-124-823-473 Sequence 473, App  
448 713 100.0 713 1 US-10-125-931-473 Sequence 473, App  
449 713 100.0 713 1 US-10-125-932-473 Sequence 473, App  
450 713 100.0 713 1 US-10-125-933-473 Sequence 473, App  
451 713 100.0 713 1 US-10-141-699-473 Sequence 473, App  
452 713 100.0 713 1 US-10-141-703-473 Sequence 473, App  
453 713 100.0 713 1 US-10-141-706-473 Sequence 473, App  
454 713 100.0 713 1 US-10-141-757-473 Sequence 473, App  
455 713 100.0 713 1 US-10-141-762-473 Sequence 473, App  
456 713 100.0 713 1 US-10-142-428-473 Sequence 473, App  
457 713 100.0 713 1 US-10-142-429-473 Sequence 473, App  
458 713 100.0 713 1 US-10-142-884-473 Sequence 473, App  
459 713 100.0 713 1 US-10-143-027-473 Sequence 473, App  
460 713 100.0 713 1 US-10-143-115-473 Sequence 473, App  
461 713 100.0 713 1 US-10-144-956-473 Sequence 473, App  
462 713 100.0 713 1 US-10-144-958-473 Sequence 473, App  
463 713 100.0 713 1 US-10-145-632-473 Sequence 473, App  
464 713 100.0 713 1 US-10-145-749-473 Sequence 473, App  
465 713 100.0 713 1 US-10-145-753-473 Sequence 473, App  
466 713 100.0 713 1 US-10-145-871-473 Sequence 473, App  
467 713 100.0 713 1 US-10-145-871-473 Sequence 473, App  
468 713 100.0 713 1 US-10-145-871-473 Sequence 473, App  
469 713 100.0 713 1 US-10-145-871-473 Sequence 473, App  
470 713 100.0 713 1 US-10-145-871-473 Sequence 473, App  
471 713 100.0 713 1 US-10-145-871-473 Sequence 473, App

472 713 100.0 713 1 US-10-145-878-473 Sequence 473, App  
473 713 100.0 713 1 US-10-146-794-473 Sequence 473, App  
474 713 100.0 713 1 US-10-147-489-473 Sequence 473, App  
475 713 100.0 713 1 US-10-147-507-473 Sequence 473, App  
476 713 100.0 713 1 US-10-147-535-473 Sequence 473, App  
477 713 100.0 713 1 US-10-147-537-473 Sequence 473, App  
478 713 100.0 713 1 US-10-152-376-473 Sequence 473, App  
479 713 100.0 713 1 US-10-152-381-473 Sequence 473, App  
480 713 100.0 713 1 US-10-152-400-473 Sequence 473, App  
481 713 100.0 713 1 US-10-153-585-473 Sequence 473, App  
482 713 100.0 713 1 US-10-157-780-473 Sequence 473, App  
483 713 100.0 713 1 US-10-157-800-473 Sequence 473, App  
484 713 100.0 713 1 US-10-157-801-473 Sequence 473, App  
485 713 100.0 713 1 US-10-157-802-473 Sequence 473, App  
486 713 100.0 713 1 US-10-158-784-473 Sequence 473, App  
487 713 100.0 713 1 US-10-158-789-473 Sequence 473, App  
488 713 100.0 713 1 US-10-192-011-473 Sequence 473, App  
489 713 100.0 713 1 US-10-139-963-473 Sequence 473, App  
490 713 100.0 713 1 US-10-140-020-473 Sequence 473, App  
491 713 100.0 713 1 US-10-140-023-473 Sequence 473, App  
492 713 100.0 713 1 US-10-140-809-473 Sequence 473, App  
493 713 100.0 713 1 US-10-140-865-473 Sequence 473, App  
494 713 100.0 713 1 US-10-141-701-473 Sequence 473, App  
495 713 100.0 713 1 US-10-141-754-473 Sequence 473, App  
496 713 100.0 713 1 US-10-142-425-473 Sequence 473, App  
497 713 100.0 713 1 US-10-142-426-473 Sequence 473, App  
498 713 100.0 713 1 US-10-142-430-473 Sequence 473, App  
499 713 100.0 713 1 US-10-143-113-473 Sequence 473, App  
500 713 100.0 713 1 US-10-146-730-473 Sequence 473, App  
501 713 100.0 713 1 US-10-146-792-473 Sequence 473, App  
502 713 100.0 713 1 US-10-158-791-473 Sequence 473, App  
503 713 100.0 713 1 US-10-156-843-473 Sequence 473, App  
504 713 100.0 713 1 US-10-157-786-473 Sequence 473, App  
505 713 100.0 713 1 US-10-219-538-376 Sequence 376, App  
506 713 100.0 713 1 US-10-147-528-473 Sequence 473, App  
507 713 100.0 713 1 US-10-128-692A-473 Sequence 473, App  
508 713 100.0 713 1 US-10-140-927-473 Sequence 473, App  
509 713 100.0 713 1 US-10-147-536-473 Sequence 473, App  
510 140 19.6 1018 1 US-10-270-470-5 Sequence 5, Appli

## ALIGNMENTS

RESULT 1  
US-09-989-722-376  
; Sequence 376, Application US/09989722  
; Patent No. US20020072067A1  
; GENERAL INFORMATION:  
; APPLICANT: Ashkenazi, Avi J.  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan L.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gerber, Hanspeter  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, J. Christopher  
; APPLICANT: Gutney, Austin L.  
; APPLICANT: Kljavin, Ivar J.  
; APPLICANT: Napier, Mary A.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas F.  
; APPLICANT: Roy, Margaret Ann  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K.  
; APPLICANT: Williams, P. Mickey  
; APPLICANT: Wood, William I.  
; APPLICANT: Zhang, Zemin





```
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-927-473

Query Match      100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTTATCATTAATCAATTAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
Db 1 AATATATCATCTATTTATCATTAATCAATTAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTCAAAACACAGCAGCAATGACATTTTCTGTCACTATTATT 120
Db 61 TTTTGGGATTTTAAATTTCAAAACACAGCAGCAATGACATTTTCTGTCACTATTATT 120
QY 121 GTTGGTATGTGAAGCTATTTTGAAGTCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
Db 121 GTTGGTATGTGAAGCTATTTTGAAGTCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
QY 181 CTTTCTATCAAGAAATAAAGAGAACCAACAGTCAACCCACACATCACTTTTAGAAGACAG 240
Db 181 CTTTCTATCAAGAAATAAAGAGAACCAACAGTCAACCCACACATCACTTTTAGAAGACAG 240
QY 241 TGTGACTCTTACCAGAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
Db 241 TGTGACTCTTACCAGAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
QY 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAACAC 360
Db 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAACAC 360
QY 361 TTAGATTCAATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTAACCTTAGTGTAA 420
Db 361 TTAGATTCAATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTAACCTTAGTGTAA 420
QY 421 GTATCCCTGTCAATATACAAATAGGTGAAATTTAAATCAGTAACTGATTTATCACTGGCTATGT 480
Db 421 GTATCCCTGTCAATATACAAATAGGTGAAATTTAAATCAGTAACTGATTTATCACTGGCTATGT 480
QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
QY 541 GCCTTAGATCTACAGGAGATCATATAATTTGATACAAATAGGAAGAAAGTGTCTCTCCCC 600
Db 541 GCCTTAGATCTACAGGAGATCATATAATTTGATACAAATAGGAAGAAAGTGTCTCTCCCC 600
QY 601 TTACAGAAATTTGACATTTTAAATGCGATACAGTTAGAAATAGGAATATGACATTAGAAAGG 660
Db 601 TTACAGAAATTTGACATTTTAAATGCGATACAGTTAGAAATAGGAATATGACATTAGAAAGG 660
QY 661 AAGAAATGACAGGGAGAAAGAAAGAAAGAAAGTGTGCGCAAGGAAAAA 713
Db 661 AAGAAATGACAGGGAGAAAGAAAGAAAGAAAGTGTGCGCAAGGAAAAA 713

RESULT 509
US-10-147-536-473
; Sequence 473, Application US/10147536
; Publication No. US20040077064A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
```

```
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C349
; CURRENT APPLICATION NUMBER: US/10/147,536
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 473
; LENGTH: 713
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-536-473

Query Match      100.0%; Score 713; DB 1; Length 713;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AATATATCATCTATTTATCATTAATCAATTAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
Db 1 AATATATCATCTATTTATCATTAATCAATTAATGATTTCTTTTATTCCTCAATAAATTTGGG 60
QY 61 TTTTGGGATTTTAAATTTCAAAACACAGCAGCAATGACATTTTCTGTCACTATTATT 120
Db 61 TTTTGGGATTTTAAATTTCAAAACACAGCAGCAATGACATTTTCTGTCACTATTATT 120
QY 121 GTTGGTATGTGAAGCTATTTTGAAGTCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
Db 121 GTTGGTATGTGAAGCTATTTTGAAGTCCAAATCAGGAAGCAACACATTTGGAGATGGCTA 180
QY 181 CTTTCTATCAAGAAATAAAGAGAACCAACAGTCAACCCACACATCACTTTTAGAAGACAG 240
Db 181 CTTTCTATCAAGAAATAAAGAGAACCAACAGTCAACCCACACATCACTTTTAGAAGACAG 240
QY 241 TGTGACTCTTACCAGAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
Db 241 TGTGACTCTTACCAGAGCTGTCAAAACACAGGCAAGGCGATAGTTAAAGACGGAATCT 300
QY 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAACAC 360
Db 301 TGAAGTCAAGAGGGTTAAATTTCTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAACAC 360
QY 361 TTAGATTCAATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTAACCTTAGTGTAA 420
Db 361 TTAGATTCAATGATTTGAAATTTAAAGCAAAATACACATATTAGTATTAACCTTAGTGTAA 420
QY 421 GTATCCCTGTCAATATACAAATAGGTGAAATTTAAATCAGTAACTGATTTATCACTGGCTATGT 480
Db 421 GTATCCCTGTCAATATACAAATAGGTGAAATTTAAATCAGTAACTGATTTATCACTGGCTATGT 480
QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
Db 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATCAGTAACTGATTTATCACTGGCTATGT 540
QY 541 GCCTTAGATCTACAGGAGATCATATAATTTGATACAAATAGGAAGAAAGTGTCTCTCCCC 600
Db 541 GCCTTAGATCTACAGGAGATCATATAATTTGATACAAATAGGAAGAAAGTGTCTCTCCCC 600
QY 601 TTACAGAAATTTGACATTTTAAATGCGATACAGTTAGAAATAGGAATATGACATTAGAAAGG 660
Db 601 TTACAGAAATTTGACATTTTAAATGCGATACAGTTAGAAATAGGAATATGACATTAGAAAGG 660
QY 661 AAGAAATGACAGGGAGAAAGAAAGAAAGAAAGTGTGCGCAAGGAAAAA 713
Db 661 AAGAAATGACAGGGAGAAAGAAAGAAAGAAAGTGTGCGCAAGGAAAAA 713

RESULT 510
```

US-10-270-470-5  
; Sequence 5, Application US/10270470  
; Publication No. US20030162955A1  
; GENERAL INFORMATION:  
; APPLICANT: Chalus, Lionel  
; APPLICANT: Quan, Ahn B.  
; APPLICANT: Bates, Elizabeth Ester Mary  
; APPLICANT: Gorman, Daniel M.  
; APPLICANT: Saeland, Sem  
; APPLICANT: Lebecque, Serge J.E.  
; APPLICANT: Phillips, Joseph H.  
; TITLE OF INVENTION: ISOLATED MAMMALIAN MEMBRANE PROTEIN GENES; RELATED REAGENTS  
; FILE REFERENCE: DX0802QK  
; CURRENT APPLICATION NUMBER: US/10/270,470  
; CURRENT FILING DATE: 1999-03-16  
; PRIOR APPLICATION NUMBER: US 09/270,368  
; PRIOR FILING DATE: 1999-03-16  
; PRIOR APPLICATION NUMBER: US 60/078,334  
; PRIOR FILING DATE: 1998-03-17  
; NUMBER OF SEQ ID NOS: 10  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 5  
; LENGTH: 1018  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: (160)..(900)  
; OTHER INFORMATION:  
US-10-270-470-5

Query Match 19.6%; Score 140; DB 1; Length 1018;  
Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
Matches 140; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 134 GCTATTGGAGATCCAATTTCAGGAAGCAACACATTGGAGAAATGGCTACTTTCTATCAAGA 193  
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
361 GCTATTGGAGATCCAATTTCAGGAAGCAACACATTGGAGAAATGGCTACTTTCTATCAAGA 420  
QY 194 AATAAGAGAACACAGTCAACCCACACATCATCTTTAGAGACAGTGTGACTCTCTACC 253  
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
421 AATAAGAGAACACAGTCAACCCACACATCATCTTTAGAGACAGTGTGACTCTCTACC 480  
QY 254 AAAGCTGTCAAAACACAGG 273  
Db ||||||||||||||||||||  
481 AAAGCTGTCAAAACACAGG 500

Search completed: June 2, 2004, 16:49:49  
Job time : 184 secs





source	1. 713	Score 713; DB 1; Length 713;			
	/organism="Homo sapiens"				
	/mol_type="unassigned DNA"				
	/db_xref="taxon:9606"				
Query Match	100.0%;	Score 713; DB 1; Length 713;			
Best Local Similarity	100.0%;	Pred. No. 4.7;			
Matches	713; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
Qy	1	AAATATCATCTATTATTCATTAATCAATTAATGATTTCTTTTATTCCTCAATTAACATTTGGG	60		
Db	1	AAATATCATCTATTATTCATTAATCAATTAATGATTTCTTTTATTCCTCAATTAACATTTGGG	60		
Qy	61	TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTCATTATTATT	120		
Db	61	TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTCATTATTATT	120		
Qy	121	GTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA	180		
Db	121	GTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA	180		
Qy	181	CTTCTATCAAGAAATAAGAGAACACACAGTCACACCCACACCAATCTTTAGAGACAG	240		
Db	181	CTTCTATCAAGAAATAAGAGAACACACAGTCACACCCACACCAATCTTTAGAGACAG	240		
Qy	241	TGTGACTCCTACCAAGCTCTCAAAACCCACAGGCAAGGCAATAGTTAAAGACGGAATCT	300		
Db	241	TGTGACTCCTACCAAGCTCTCAAAACCCACAGGCAAGGCAATAGTTAAAGACGGAATCT	300		
Qy	301	TGACTCAAGGGTAAATCTTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC	360		
Db	301	TGACTCAAGGGTAAATCTTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC	360		
Qy	361	TTAGATTCATGATTTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAAAT	420		
Db	361	TTAGATTCATGATTTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAAAT	420		
Qy	421	GTATCCCTGTCATATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC	480		
Db	421	GTATCCCTGTCATATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC	480		
Qy	481	AGTTCTAAATTTGACCTTTTAAATTTTAAATCAGTAACCTGATTTCACTGGCTATGT	540		
Db	481	AGTTCTAAATTTGACCTTTTAAATTTTAAATCAGTAACCTGATTTCACTGGCTATGT	540		
Qy	541	GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAGGAAAGTGTCTCTCCCC	600		
Db	541	GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAGGAAAGTGTCTCTCCCC	600		
Qy	601	TTACAGAAATTCACATTTTAAATTCGGATACAGTTAGAAATAGCAATTAGAAGG	660		
Db	601	TTACAGAAATTCACATTTTAAATTCGGATACAGTTAGAAATAGCAATTAGAAGG	660		
Qy	661	AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCGCAAGGAAAAA 713			
Db	661	AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCGCAAGGAAAAA 713			
RESULT 3	AX403489	713 bp	DNA	linear	PAT 14-JUN-2002
LOCUS	AX403489	Sequence 376 from Patent WO0073454.			
DEFINITION	AX403489				
ACCESSION	AX403489.1	GI:21436980			
VERSION					
KEYWORDS					
SOURCE					
ORGANISM					
	Homo sapiens				
REFERENCE					
AUTHORS					
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
	1				
	Ashkenazi,A.J., Baker,K.P., Botstein,D., Desnovers,L., Eaton,D.,				
	Ferrara,N., Gerber,H., Gerritsen,M., Goddard,A., Godowski,P.,				
	Grimaldi,C.J., Gurney,A.L., Kljavin,I., Napier,M.A., Pan,J.,				

Paoni,N.F., ROY,M., Stewart,T.A., Tumas,D., Watanabe,C.K.,					
Williams,P., Wood,W.I. and Zhang,Z.					
Secreted and transmembrane polypeptides and nucleic acids encoding					
the same					
Patent: WO 0073454-A 376 07-DEC-2000;					
Genentech Inc. (US)					
Location/Qualifiers					
1. 713					
/organism="Homo sapiens"					
/mol_type="unassigned DNA"					
/db_xref="taxon:9606"					
Query Match	100.0%;	Score 713; DB 1; Length 713;			
Best Local Similarity	100.0%;	Pred. No. 4.7;			
Matches	713; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
Qy	1	AAATATCATCTATTATTCATTAATCAATTAATGATTTCTTTTATTCCTCAATTAACATTTGGG	60		
Db	1	AAATATCATCTATTATTCATTAATCAATTAATGATTTCTTTTATTCCTCAATTAACATTTGGG	60		
Qy	61	TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTCATTATTATT	120		
Db	61	TTTTGGGATTTAAATTTTCAACACAGCAGAAATGACATTTTCTGTCTCATTATTATT	120		
Qy	121	GTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA	180		
Db	121	GTGGTATGTAAGCTATTTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGCTA	180		
Qy	181	CTTCTATCAAGAAATAAGAGAACACACAGTCACACCCACACCAATCTTTAGAGACAG	240		
Db	181	CTTCTATCAAGAAATAAGAGAACACACAGTCACACCCACACCAATCTTTAGAGACAG	240		
Qy	241	TGTGACTCCTACCAAGCTCTCAAAACCCACAGGCAAGGCAATAGTTAAAGACGGAATCT	300		
Db	241	TGTGACTCCTACCAAGCTCTCAAAACCCACAGGCAAGGCAATAGTTAAAGACGGAATCT	300		
Qy	301	TGACTCAAGGGTAAATCTTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC	360		
Db	301	TGACTCAAGGGTAAATCTTGTGCTGAAGCTGGGCGAGGGTGTAAAGAAAACAC	360		
Qy	361	TTAGATTCATGATTTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAAAT	420		
Db	361	TTAGATTCATGATTTAAATTTAAGGCAATACACATATTAGTATTACCTTAGTGTAAAT	420		
Qy	421	GTATCCCTGTCATATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC	480		
Db	421	GTATCCCTGTCATATATACAAATAAGGTGAAATTAATAGTACCCTATGCGCTGGAC	480		
Qy	481	AGTTCTAAATTTGACCTTTTAAATTTTAAATCAGTAACCTGATTTCACTGGCTATGT	540		
Db	481	AGTTCTAAATTTGACCTTTTAAATTTTAAATCAGTAACCTGATTTCACTGGCTATGT	540		
Qy	541	GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAGGAAAGTGTCTCTCCCC	600		
Db	541	GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAGGAAAGTGTCTCTCCCC	600		
Qy	601	TTACAGAAATTCACATTTTAAATTCGGATACAGTTAGAAATAGCAATTAGAAGG	660		
Db	601	TTACAGAAATTCACATTTTAAATTCGGATACAGTTAGAAATAGCAATTAGAAGG	660		
Qy	661	AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCGCAAGGAAAAA 713			
Db	661	AAGAATGACAGGAGAAAGGAAAGGAAAGTGTGCGCAAGGAAAAA 713			
RESULT 4	AX464340	713 bp	DNA	linear	PAT 16-JUL-2002
LOCUS	AX464340	Sequence 473 from Patent WO0140466.			
DEFINITION	AX464340				
ACCESSION	AX464340.1	GI:21899186			
VERSION					
KEYWORDS					
SOURCE					
	Homo sapiens				



Db 301 TGACTCAAGAGGGTTAATCTTGCTGCTGAAGCTGGGGCAGGGGCTTAAGAAAAACAC 360

QY 361 TTAGATTCATGATGTTAAATTTAAGGCAATACACATATAGTATTAACCTTAGTGTAAAT 420

Db 361 TTAGATTCATGATGTTAAATTTAAGGCAATACACATATAGTATTAACCTTAGTGTAAAT 420

QY 421 GTATCCCTGTCATATACATATAGTGTAAATTTAAGTATACCTTATGAGTGGCTGGAC 480

Db 421 GTATCCCTGTCATATACATATAGTGTAAATTTAAGTATACCTTATGAGTGGCTGGAC 480

QY 481 AGTCTAAATTTGACTTTATTAATTTTAAATCAGTAACTGATTTATCATGCTATGT 540

Db 481 AGTCTAAATTTGACTTTATTAATTTTAAATCAGTAACTGATTTATCATGCTATGT 540

QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATCAAAATTAAGAAAGTGTCTCTCCCC 600

Db 541 GCTTAGATCTACAGGAGATCATATAATTTGATCAAAATTAAGAAAGTGTCTCTCCCC 600

QY 601 TTACAGAAATGACATTTTAAATGCGATACAGTATAGATAGGAAATATGACATTAGAAGG 660

Db 601 TTACAGAAATGACATTTTAAATGCGATACAGTATAGATAGGAAATATGACATTAGAAGG 660

QY 661 AAGAAATGACGGGAGAAAGAAAGAAAGTGTGCGCAAGGAAAAAAA 713

Db 661 AAGAAATGACGGGAGAAAGAAAGAAAGTGTGCGCAAGGAAAAAAA 713

## RESULT 6

AC024224/c

LOCUS

DEFINITION Homo sapiens 12 BAC RP11-1331i4 (Roswell Park Cancer Institute Human BAC Library) complete sequence.

AC024224

VERSION AC024224.33 GI:21240476

KEYWORDS HIG.

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 165414)

Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C., Alsbrooks,S.B., Amarantunge,H.C., Are,J.R., Ayele,M., Banks,T., Barbara,J., Benton,J., Benge,K., Blankenburg,K., Bonnin,D., Bouck,J., Bowie,S., Brivaga,M., Brown,E., Brown,M., Bryant,N.P., Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C., Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D., Chen,G., Chen,R., Chen,Z., Chiu,D., Chowdhry,I., Christopoulos,C., Cleveland,C.D., Cox,C., Coyie,M.D., Dathorne,S.R., David,R., Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H., Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J., Earhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Emerling,S., Escotto,M., Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P., Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R., Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K., Han,J., Harris,C., Harris,K., Hart,M., Havlik,P., Hawes,A., Hernandez,J., Hernandez,O., Hodgson,A., Hogues,M., Holloway,C., Hollins,B., Homs,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Ioshikhes,I., Jackson,L.E., Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S., Karlsson,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C., Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lee,B., Lewis,L.C., Lewis,L., Li,J., Li,Z., Lichtarge,O., Liu,C., Liu,J., Liu,W., Louleghed,H., Lozada,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J., Maheshwari,M., Mapua,P., Marondel,I., Martin,R., Martindale,A., Martinez,E., Massey,B., Mashiney,E., McLeod,M.P., Meador,M., Mei,G., Merscher,S., Metzker,M., Miller,A., Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Montgomery,K.T., Morgan,M., Morris,S., Moser,M., Neal,D., Nelson,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N., Nguyen,N., Nickerson,E., Nwokenkwo,S., Ogih,M., Okuwonu,G., Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peary,J., Perez,L., Peters,L., Pickens,R., Primus,E., Pu,J.L., Quiles,M., Ren,Y., Rives,M., Rojas,A., Rojubokan,I., Rolfe,M., Ruiz,S., Savery,G.,

Scherer,S., Scott,G., Shen,H., Shim,C., Shooshitari,N., Sisson,I., Sodergren,E., Sonaike,T., Sparks,A., Stanley,H., Stone,H., Sutton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H., Tansey,J., Taylor,C., Taylor,T., Telford,B., Thomas,N., Thomas,S., Umami,K., Vazquez,L., Vera,V., Villaion,D., Vinson,R., Wang,Q., Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S., Williams,G., Williamson,A., Wleczyk,R., Wooden,S., Worley,K., Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Kucherlapati,R., Weinstock,G. and Gibbs,R.

Direct Submission

Unpublished

2 (bases 1 to 165414)

Worley,K.C.

Direct Submission

Submitted (28-FEB-2000) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

3 (bases 1 to 165414)

Worley,K.C.

Direct Submission

Submitted (26-MAY-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

4 (bases 1 to 165414)

Worley,K.C.

Direct Submission

Submitted (29-MAY-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

On May 29, 2002 this sequence version replaced gi:21206012.

INFORMATION: <http://www.hgsc.bcm.tmc.edu/> or email

gc-help@bcm.tmc.edu

CLONE LENGTH: This sequence does not necessarily represent the entire insert of this clone. Overlapping regions of clones are only sequenced and submitted once, so the sequence for the remainder of the insert may be found in the record for the adjacent clones. Overlapping clones are noted at the beginning and end of the Features listing.

## ANNOTATION OF FEATURES:

STSs are identified using ePCR (Genome Res. 7:541-550) searches of a local database that includes entries from dbSTS, GDB, and local mapping efforts.

Repeats are identified using RepeatMasker (A. Smit and P. Green, unpublished.) for Human and Mouse sequences.

Genes and Region of sequence similarity are identified by BLAST (Nuc. Acids Res. 25:3389-3402) similarity (expect < 1e-34) to the EST and cDNA sequences. Genes demonstrate at least two exons flanked by consensus splice sites that maintained sequence continuity across the splice junctions. Sequences that are not identical matches are annotated as similar.

SEQUENCING READ COVERAGE: Sequencing is completed to a minimum standard of double strand coverage with a minimum of 2 clones and 2 reads with no ambiguities or 2 chemistries with a minimum of 2 clones and 3 reads with no ambiguities. If the sequence quality for a region does not meet this standard, it will be indicated in the annotation as Low Coverage.

QUALITY OF INDIVIDUAL BASES: This sequence meets stringent quality standards - estimated error rate less than 1 per 10,000 bases. Reports of low quality individual bases and measures of base quality are listed below. Description of the metrics can be found at URL:

<http://gc.bcm.tmc.edu:8088/quality.info/genbank.annotation.html>.

## QUALSTAT REPORT.

Location/Qualifiers  
1. 165414  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

FEATURES  
source





```
Db 211451 GAATCTTGACTCAAAGAGGGTTAAATCTTGTTGCTGAAGCCTGGGCGAGGTGTAAGA 211392
QY 354 AAAACACATTAGATTCATGATGTAATTTAAAGGCAAAATACACATATTAGTATTACCTTA 413
Db 211391 AAAACACATTAGATTCATGATGTAATTTAAAGGCAAAATACACATATTAGTATTACCTTA 211332
QY 414 GTGTAATGATCCCTGCTCATATATACAAATAAGGTGAATTTATAAGTACCTATGCAAGTTG 473
Db 211331 GTGTAATGATCCCTGCTCATATATACAAATAAGGTGAATTTATAAGTACCTATGCAAGTTG 211272
QY 474 GGTGACAGCTTCTAAATTCGACTTTTAAATTTTAAATTCAGTAACTGATTTATCAGT 533
Db 211271 GGTGACAGCTTCTAAATTCGACTTTTAAATTTTAAATTCAGTAACTGATTTATCAGT 211212
QY 534 GCTATGCTTATGATCTACAGGAGATCATATATTTTATGATCAATTAAGGAAAGGTTTC 593
Db 211211 GCTATGCTTATGATCTACAGGAGATCATATATTTTATGATCAATTAAGGAAAGGTTTC 211152
QY 594 TCT--CCCCTTACAGAAATGACATTTTAAATTCGATACAGTTAGATAGCAATATGACA 651
Db 211151 TCTGCGCCTTACAGAAATGACATTTTAAATTCGATACAGTTAGATAGCAATATGACA 211092
QY 652 TTAGAAGGAAGATGACAGGGGAGAAAGGAAGGAAATGTTGCCAAGGAAA 708
Db 211091 TTAGAAGGAAGATGACAGGGGAGACAGGAAGACGGGAAATGTTGCCAAGGAAAT 211035

RESULT 8
AC138620/c
LOCUS
DEFINITION Mus musculus chromosome UNK clone RP23-250E1, WORKING DRAFT
SEQUENCE, 13 unordered pieces.
AC138620
VERSION AC138620.2 GI:28557995
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT; HTGS_FULLTOP.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 221471)
McPherson,J.D. and Waterston,R.H.
The sequence of Mus musculus clone
Unpublished
2 (bases 1 to 221471)
McPherson,J.D. and Waterston,R.H.
Direct Submission
Submitted (12-JAN-2003) Genome Sequencing Center, 4444 Forest Park
Parkway, St. Louis, MO 63108, USA
3 (bases 1 to 221471)
McPherson,J.D. and Waterston,R.H.
Direct Submission
Submitted (25-FEB-2003) Genome Sequencing Center, 4444 Forest Park
Parkway, St. Louis, MO 63108, USA
On Feb 25, 2003 this sequence version replaced gi:27657609.

----- Genome Center -----
Center: Washington University Genome Sequencing Center
Center code: WUGSC
Web site: http://genome.wustl.edu/gsc/index.shtml
Contact: submissions@wustl.edu
----- Project Information -----
Center project name: M.BA0250E01
----- Summary Statistics -----
Sequencing vector: M13, 0%
Sequencing method: plasmid, 100%
Chemistry: Dye-terminator Big Dye, 100% of reads
Assembly program: Phrap; version 0.990319
Consensus quality: 21739 bases at least Q40
Consensus quality: 218068 bases at least Q30
Consensus quality: 218373 bases at least Q20
```

```
Insert size: 193000; agarose-fp
Insert size: 227132; sum-of-contigs
Quality coverage: 14.88 in Q20 bases; agarose-fp
Quality coverage: 12.33 in Q20 bases; sum-of-contigs
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 13 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
*
* 1 1509: contig of 1509 bp in length
* 1510 1509: gap of unknown length
* 1610 3423: contig of 1814 bp in length
* 3424 3524: gap of unknown length
* 3524 8474: contig of 4950 bp in length
* 8474 8574: gap of unknown length
* 8574 13990: contig of 5417 bp in length
* 13991 14090: gap of unknown length
* 14091 20220: contig of 6130 bp in length
* 20221 20321: gap of unknown length
* 20321 33395: contig of 13075 bp in length
* 33396 3496: gap of unknown length
* 3496 46732: contig of 13236 bp in length
* 46732 46832: gap of unknown length
* 46832 62519: contig of 15687 bp in length
* 62519 62619: gap of unknown length
* 62619 80893: contig of 18274 bp in length
* 80893 80993: gap of unknown length
* 80993 103313: contig of 22320 bp in length
* 103313 103413: gap of unknown length
* 103413 125915: contig of 22502 bp in length
* 125915 126015: gap of unknown length
* 126015 171459: contig of 45445 bp in length
* 171460 171559: gap of unknown length
* 171560 221471: contig of 49912 bp in length.

FEATURES
source
1..221471
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/chromosome="UNK"
/clone="RP23-250E1"
1..1509
/notes="assembly_name:Contig19"
1610..3423
/notes="assembly_name:Contig21"
3524..8473
/notes="assembly_name:Contig22"
8574..13990
/notes="assembly_name:Contig23"
14091..20220
/notes="assembly_name:Contig24"
20321..33395
/notes="assembly_name:Contig25"
33496..46731
/notes="assembly_name:Contig26"
46832..62518
/notes="assembly_name:Contig27"
62619..80892
/notes="assembly_name:Contig28"
80993..103312
/notes="assembly_name:Contig29"
103413..125914
/notes="assembly_name:Contig30"
126015..171459
/notes="assembly_name:Contig31"
171560..221471
/notes="assembly_name:Contig32"

Query Match 29.7%; Score 211.499; DB 1; Length 221471;
```

Best Local Similarity 63.2%; Pred. No. 1.7;  
Matches 456; Conservative 0; Mismatches 215; Indels 51; Gaps 9;

Qy 1 AATATATCATCTATTATTAATCAATTAATGATGATTTCT-TTATTCANTAAACATTTGG 59  
Db 87112 AACATACAGTTTATTAATCAATTAATGATGATTTCT-TTATTCANTAAACATTTGG 59  
Qy 60 GTTTTGGGATTTAAATTTTCAACACACAGAGATGACAT--TTTTCTGTCACTATTATT 117  
Db 87052 GTGCTGCAATTTCCATTTTAAACACACAGAGATGACTTTCTTTCTGTCACTATTGCT 86993  
Qy 118 ATTCTTGGTATGAGAGATTTGGAGATCCAAATTCAGGAAGCAACATTTGGAGATGG 177  
Db 86992 GTTCGTGACGTATGAAGCATTTTGGTGACACAAATTCAGGGAGAAATCCAGAGGAGAAAG 86933  
Qy 178 CTACTTTCTATCAAGAAATAAGAGAACCAAGTCAACCCACACCAATCATCTTTAGAGA 237  
Db 86932 CACTTCTTATCAAGAAATAAGAGAACCAACA---AGCCACAGATCATCTTTAGATGA 86876  
Qy 238 CAGTGTGACTCCTACCAAGCTGTCAAAACACAGGCAAGGCATAGTTAAAGGA----- 292  
Db 86875 GAAGTGGCTCCCTCCAAAGCATCCCAACTACAGGCAAGGCAGACGAGGAGCAAT 86816  
Qy 293 CGGAATCTTCACTCAAGAGGGTTAAATCTTGGTGTCTGAAGCTGGGGCAGGGGTGTAAG 352  
Db 86815 GGGATCCCGGATTCAGAGGTTTCAATTTCTGGTGTCTGAGGCTGGGGTGGGG----- 86764  
Qy 353 AAAAAACATTAGATTCAATGATTTAAATTTAAGGCAAAATACACATATTAGTATTACCTT 412  
Db 86763 -AATATGTTTACATCTACTAACAGTGAATTCAGGCAAGCAGACCTAACAGAAATCCCTT 86705  
Qy 413 AGTGAATGATCCCTGTCTATATATAACAATAAGGTGAATTAAGTACCCCTATGCAAGTT 472  
Db 86704 AGCATAACATA-CCCTGCCAGACAGCTGTTAAAGTGGCATCACAAATCCACAGCTC--- 86650  
Qy 473 GGCTGGACAGTTCTAAATTTGACATTTTAAATTTTAAATCAGTAAGTAT-TTATCAC 531  
Db 86649 -----TTTCACTTAAAGGAGCAGTAACAGCTTTATCTC 86612  
Qy 532 TGGCTATGTTGTTAGATCTACAGGAGATCATATAATTTGATACAAATAAAGAAAGTGT 591  
Db 86611 TGGCTGTGCTGAATCTATGAGACATGATAGAAATTTGATGCAAAAGAGGGGTAGTGT 86552  
Qy 592 TCTCTCCCTTACAGAAATGACATTTTAAATGCGATACAGTTAGAAATATGACA 651  
Db 86551 TCAGTGTCTTATGGAATGATATTTTACAGTGTAT---GTTAGAAATAGATAGATGTA 86495  
Qy 652 TTAGAAAGGAGATGACAGGAGAAAGAGGAAATGTTGCCAAGGAAAGAA 711  
Db 86494 GGGAAAGAAATATAAGGGAAATGAGGAAGGACACTGAAGACTGTAAATGCTAATAA 86435  
Qy 712 AA 713  
Db 86434 TA 86433

Search completed: June 2, 2004, 16:22:42  
Job time : 229 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2004, 16:29:06 ; Search time 54 Seconds  
(without alignments)

4.019 Million cell updates/sec

Title: US-09-989-293A-376

Perfect score: 713

Sequence: 1 aatatacatctattatca.....tggtgcaaggaaaaaaa 713

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 207 seqs, 152209 residues

Total number of hits satisfying chosen parameters: 414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 207 summaries

Database : rng376.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	713	100.0	713	1	AAZ65094
2	713	100.0	713	1	AAC58634
3	713	100.0	713	1	AAS21480
4	713	100.0	713	1	AAAF44240
5	713	100.0	713	1	ABX77952
6	713	100.0	713	1	ABX80364
7	713	100.0	713	1	ACA69270
8	713	100.0	713	1	ACD24089
9	713	100.0	713	1	ABX90341
10	713	100.0	713	1	ABX64187
11	713	100.0	713	1	ACA67230
12	713	100.0	713	1	ACA64409
13	713	100.0	713	1	ACA03839
14	713	100.0	713	1	ABX83377
15	713	100.0	713	1	ABX80868
16	713	100.0	713	1	ACD44377
17	713	100.0	713	1	ACD42031
18	713	100.0	713	1	ABX79548
19	713	100.0	713	1	ACA93569
20	713	100.0	713	1	ABX81251
21	713	100.0	713	1	ACA04260
22	713	100.0	713	1	ACA93067
23	713	100.0	713	1	ABX17151
24	713	100.0	713	1	ACA68006
25	713	100.0	713	1	ACA88455
26	713	100.0	713	1	ACD81962
27	713	100.0	713	1	ADA45992
28	713	100.0	713	1	ADA76423
29	713	100.0	713	1	ADA19073
30	713	100.0	713	1	ADA61696
31	713	100.0	713	1	ADB19481
32	713	100.0	713	1	ADB28022
33	713	100.0	713	1	ADA86501

34	713	100.0	713	1	ADB16065	Human PRO polynuc
35	713	100.0	713	1	ADA37887	Human cDNA encodin
36	713	100.0	713	1	ADA47851	Human PRO polynuc
37	713	100.0	713	1	ADA21573	Human cDNA encodin
38	713	100.0	713	1	ADA10360	Human cDNA encodin
39	713	100.0	713	1	ADA67646	Human PRO polynuc
40	713	100.0	713	1	ADB30653	cDNA encoding huma
41	713	100.0	713	1	ADA85949	Novel human secret
42	713	100.0	713	1	ADA17904	cDNA encoding huma
43	713	100.0	713	1	ADA97161	Human PRO polynuc
44	713	100.0	713	1	ADA79455	Human PRO polynuc
45	713	100.0	713	1	ADA67604	Novel human secret
46	713	100.0	713	1	ADB16806	Human PRO polynuc
47	713	100.0	713	1	ADA28012	Human cDNA encodin
48	713	100.0	713	1	ADA91898	Novel human secret
49	713	100.0	713	1	ADB14951	Human PRO polynuc
50	713	100.0	713	1	ADB18922	Novel human secret
51	713	100.0	713	1	ADA94137	Human PRO polynuc
52	713	100.0	713	1	ADB20033	Novel human secret
53	713	100.0	713	1	ADB13345	Human PRO polynuc
54	713	100.0	713	1	ACD98660	Novel human secret
55	713	100.0	713	1	ADA94592	Human cDNA encodin
56	713	100.0	713	1	ADA74539	Human PRO polynuc
57	713	100.0	713	1	ADB24832	Human PRO polynuc
58	713	100.0	713	1	ADA62356	Human PRO polynuc
59	713	100.0	713	1	ADA75319	Human PRO polynuc
60	713	100.0	713	1	ADA85397	Novel human secret
61	713	100.0	713	1	ADA84845	Novel human secret
62	713	100.0	713	1	ADB30101	cDNA encoding huma
63	713	100.0	713	1	ADA80629	Human PRO polynuc
64	713	100.0	713	1	ADA75871	Human PRO polynuc
65	713	100.0	713	1	ADA38817	Human cDNA encodin
66	713	100.0	713	1	ADA47096	Human PRO polynuc
67	713	100.0	713	1	ADB25392	Human PRO polynuc
68	713	100.0	713	1	ADA93568	Human PRO polynuc
69	713	100.0	713	1	ADB26918	cDNA encoding huma
70	713	100.0	713	1	ADB31205	cDNA encoding huma
71	713	100.0	713	1	ADA92938	Human cDNA encodin
72	713	100.0	713	1	ADA61133	Homo sapiens, Nov
73	713	100.0	713	1	ADB24280	Human PRO polynuc
74	713	100.0	713	1	ADA96609	Human PRO polynuc
75	713	100.0	713	1	ADA81181	Human PRO polynuc
76	713	100.0	713	1	ADA96057	Human PRO polynuc
77	713	100.0	713	1	ADB26366	cDNA encoding huma
78	713	100.0	713	1	ADB21851	Novel human secret
79	713	100.0	713	1	ADA77630	Human PRO polynuc
80	713	100.0	713	1	ADB18370	cDNA encoding huma
81	713	100.0	713	1	ADA87053	Novel human secret
82	713	100.0	713	1	ADA88156	Novel human secret
83	713	100.0	713	1	ADA46544	Novel human secret
84	713	100.0	713	1	ADB28574	cDNA encoding huma
85	713	100.0	713	1	ADB29126	cDNA encoding huma
86	713	100.0	713	1	ACH65523	Human cDNA encodin
87	713	100.0	713	1	ADA77078	Human PRO polynuc
88	713	100.0	713	1	ADA22499	Human cDNA encodin
89	713	100.0	713	1	ADA88708	Novel human secret
90	713	100.0	713	1	ADA97713	Human PRO polynuc
91	713	100.0	713	1	ADB27470	cDNA encoding huma
92	713	100.0	713	1	ADB22403	Novel human secret
93	713	100.0	713	1	ACD39513	Human cDNA encodin
94	713	100.0	713	1	ADA06665	Human secreted/tra
95	713	100.0	713	1	ADA39358	Human cDNA encodin
96	713	100.0	713	1	ADA67094	Human PRO polynuc
97	713	100.0	713	1	ADB22955	Human PRO polynuc
98	713	100.0	713	1	ADB23728	Human PRO polynuc
99	713	100.0	713	1	ADA92450	Novel human secret
100	713	100.0	713	1	ADB15513	Human PRO polynuc
101	713	100.0	713	1	ADB36765	Novel human secret
102	713	100.0	713	1	ADB96384	Human PRO polynuc
103	713	100.0	713	1	ADB38213	Novel human secret
104	713	100.0	713	1	ADB66685	Novel human secret
105	713	100.0	713	1	ADB89765	Human PRO polynuc
106	713	100.0	713	1	ADB90497	Human PRO polynuc

107 713 100.0 713 1 ADB39598 Novel human secret  
108 713 100.0 713 1 ADB47221 Novel human secret  
109 713 100.0 713 1 ADB86828 Human PRO polynucleotide  
110 713 100.0 713 1 ADB77433 Novel human secret  
111 713 100.0 713 1 ADB34590 Human PRO polynucleotide  
112 713 100.0 713 1 ADB35694 Human PRO polynucleotide  
113 713 100.0 713 1 ADB34038 Human PRO polynucleotide  
114 713 100.0 713 1 ADB35142 Human PRO polynucleotide  
115 713 100.0 713 1 ADB36246 Human PRO polynucleotide  
116 713 100.0 713 1 ADB46641 Human PRO polynucleotide  
117 713 100.0 713 1 ADC57856 Human PRO polynucleotide  
118 713 100.0 713 1 ADC55220 Human PRO polynucleotide  
119 713 100.0 713 1 ADC12087 Human cDNA encoding  
120 713 100.0 713 1 ADC56504 Human cDNA encoding  
121 713 100.0 713 1 ADC07569 Human cDNA encoding  
122 713 100.0 713 1 ADC11554 Human cDNA encoding  
123 713 100.0 713 1 ADC50514 Novel human secret  
124 713 100.0 713 1 ADC72061 Novel human secret  
125 713 100.0 713 1 ADC60040 Novel human secret  
126 713 100.0 713 1 ADC53047 Novel human secret  
127 713 100.0 713 1 ADC57401 Novel human secret  
128 713 100.0 713 1 ADC60592 Novel human secret  
129 713 100.0 713 1 ADC51067 Novel human secret  
130 713 100.0 713 1 ADC65594 Novel human secret  
131 713 100.0 713 1 ADC54592 Novel human secret  
132 713 100.0 713 1 ADC53653 Novel human secret  
133 713 100.0 713 1 ADC59176 Novel human secret  
134 713 100.0 713 1 ADC56054 Novel human secret  
135 713 100.0 713 1 ADC58624 Novel human secret  
136 713 100.0 713 1 ADC14676 Novel human secret  
137 713 100.0 713 1 ADD08208 Novel human secret  
138 713 100.0 713 1 ADD03298 Novel human secret  
139 713 100.0 713 1 ADC90290 Novel human secret  
140 713 100.0 713 1 ADC82033 Human PRO polynucleotide  
141 713 100.0 713 1 ADC69709 cDNA encoding human  
142 713 100.0 713 1 ADC48598 Human PRO polynucleotide  
143 713 100.0 713 1 ADD10127 Human PRO polynucleotide  
144 713 100.0 713 1 ADD07675 Novel human secret  
145 713 100.0 713 1 ADD04702 Novel human secret  
146 713 100.0 713 1 ADC82566 Human PRO polynucleotide  
147 713 100.0 713 1 ADC80858 Human PRO polynucleotide  
148 713 100.0 713 1 ADD11165 Human PRO polynucleotide  
149 713 100.0 713 1 ADC48046 Human PRO polynucleotide  
150 713 100.0 713 1 ADD08746 Novel human secret  
151 713 100.0 713 1 ADC80106 Novel human secret  
152 713 100.0 713 1 ADD06995 Novel human secret  
153 713 100.0 713 1 ADD09575 Human PRO polynucleotide  
154 713 100.0 713 1 ADC83242 Human PRO polynucleotide  
155 713 100.0 713 1 ADD41288 Human PRO polynucleotide  
156 713 100.0 713 1 ADD52427 cDNA encoding human  
157 713 100.0 713 1 ADD53167 cDNA encoding human  
158 713 100.0 713 1 ADD53719 Novel human secret  
159 713 100.0 713 1 ADD55349 Human PRO polynucleotide  
160 713 100.0 713 1 ADD56307 Human PRO polynucleotide  
161 713 100.0 713 1 ADD51875 cDNA encoding human  
162 713 100.0 713 1 ADD02674 Human PRO polynucleotide  
163 713 100.0 713 1 ADD02108 Human PRO polynucleotide  
164 713 100.0 713 1 ADD54230 Novel human secret  
165 713 100.0 713 1 ADD54745 Human PRO polynucleotide  
166 713 100.0 713 1 ADD92607 Human PRO polynucleotide  
167 713 100.0 713 1 ADD91503 Human PRO polynucleotide  
168 713 100.0 713 1 ADE04117 Human PRO polynucleotide  
169 713 100.0 713 1 ADE26899 Novel human secret  
170 713 100.0 713 1 ADE32414 Novel human secret  
171 713 100.0 713 1 ADE23246 cDNA encoding human  
172 713 100.0 713 1 ADE79570 cDNA encoding human  
173 713 100.0 713 1 ADE42106 Human PRO polynucleotide  
174 713 100.0 713 1 ADE17923 Human PRO polynucleotide  
175 713 100.0 713 1 ADE26055 Human PRO polynucleotide  
176 713 100.0 713 1 ADE33518 Novel human secret  
177 713 100.0 713 1 ADE34070 Novel human secret  
178 713 100.0 713 1 ADE80122 cDNA encoding human  
179 713 100.0 713 1 ADD93159 Human PRO polynucleotide

180 713 100.0 713 1 ADE19579 Human PRO polynucleotide  
181 713 100.0 713 1 ADE19027 Human PRO polynucleotide  
182 713 100.0 713 1 ADE43223 Human PRO polynucleotide  
183 713 100.0 713 1 ADD96012 Human PRO polynucleotide  
184 713 100.0 713 1 ADE22898 cDNA encoding human  
185 713 100.0 713 1 ADD79016 cDNA encoding human  
186 713 100.0 713 1 ADE26366 Novel human secret  
187 713 100.0 713 1 ADE32966 Novel human secret  
188 713 100.0 713 1 ADE42658 Human PRO polynucleotide  
189 713 100.0 713 1 ADD80674 cDNA encoding human  
190 713 100.0 713 1 ADD89702 Human PRO polynucleotide  
191 713 100.0 713 1 ADE40986 Human PRO polynucleotide  
192 713 100.0 713 1 ADE04785 Human PRO polynucleotide  
193 713 100.0 713 1 ADC81210 Novel human secret  
194 713 100.0 713 1 ADD76658 Human PRO polynucleotide  
195 713 100.0 713 1 ADD88022 Human PRO polynucleotide  
196 713 100.0 713 1 ADD86426 Human PRO polynucleotide  
197 713 100.0 713 1 ADE75874 Human PRO polynucleotide  
198 713 100.0 713 1 ADE23450 cDNA encoding human  
199 713 100.0 713 1 ADE24002 cDNA encoding human  
200 713 100.0 713 1 ADE24645 cDNA encoding human  
201 713 100.0 713 1 ADD87470 Human PRO polynucleotide  
202 713 100.0 713 1 ADE89336 Human PRO polynucleotide  
203 713 100.0 713 1 ADE18475 Human PRO polynucleotide  
204 713 100.0 713 1 ADE88784 Human PRO polynucleotide  
c 205 705.6 99.0 5709 1 AAK81282 Human immune/haema  
c 206 701.5 98.4 712 1 AAK91481 Human PRO1159 cDNA  
c 207 332.8 46.7 336 1 AAK81284 Human immune/haema

## ALIGNMENTS

## RESULT 1

AAZ65094  
ID AAZ65094 standard; cDNA; 713 BP.

XX AAZ65094;

DT 05-APR-2000 (first entry)

XX Membrane-bound protein PRO1159 encoding cDNA.

DE Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;  
KW pharmacological; receptor immunoadhesin; gene mapping; ss.

XX Homo sapiens.

XX WO9963088-A2.

XX 09-DEC-1999.

XX 02-JUN-1999; 99WO-0012252.

XX 02-JUN-1999; 98US-0087607P.

XX 02-JUN-1999; 98US-0087609P.

XX 02-JUN-1999; 98US-0087759P.

XX 03-JUN-1999; 98US-0087827P.

XX 04-JUN-1999; 98US-0088021P.

XX 04-JUN-1999; 98US-0088025P.

XX 04-JUN-1999; 98US-0088028P.

XX 04-JUN-1999; 98US-0088029P.

XX 04-JUN-1999; 98US-0088030P.

XX 04-JUN-1999; 98US-0088033P.

XX 05-JUN-1999; 98US-0088167P.

XX 05-JUN-1999; 98US-0088202P.

XX 05-JUN-1999; 98US-0088212P.

XX 09-JUN-1999; 98US-0088655P.

XX 10-JUN-1999; 98US-0088722P.

XX 10-JUN-1999; 98US-0088730P.

XX 10-JUN-1999; 98US-0088734P.

QY	61	TTTTGGGATTTTAATTTTCAACACAGCAGAGATGACATTTTTCGTCTACATTAATTTAT	120	PF	17-APR-2002; 2002US-00124823.	XX
Db	61	TTTTGGGATTTTAATTTTCAACACAGCAGAGATGACATTTTTCGTCTACATTAATTTAT	120	PR	31-MAR-1997; 97WO-US005230.	XX
QY	121	GTGTGATGTGAAGCTATTTGGAGATCCAAATTCAGGAGCAACACATTCGGAAATGGCTA	180	PR	12-JUN-1998; 98WO-US012456.	PR
Db	121	GTGTGATGTGAAGCTATTTGGAGATCCAAATTCAGGAGCAACACATTCGGAAATGGCTA	180	PR	14-JUL-1998; 98WO-US014552.	PR
QY	181	CTTCTCATCAAGAAATAAGAGCAACACAGTCAACCCACACAAATCATCTTTTAAAGACAG	240	PR	28-AUG-1998; 98WO-US017883.	PR
Db	181	CTTCTCATCAAGAAATAAGAGCAACACAGTCAACCCACACAAATCATCTTTTAAAGACAG	240	PR	10-SEP-1998; 98WO-US018824.	PR
QY	241	TGTGACTCTCAACAAAGCTGTCAAACCAACAGCGCAAGGCATAGTTAAAGGACGGAATCT	300	PR	14-SEP-1998; 98WO-US019094.	PR
Db	241	TGTGACTCTCAACAAAGCTGTCAAACCAACAGCGCAAGGCATAGTTAAAGGACGGAATCT	300	PR	14-SEP-1998; 98WO-US019177.	PR
QY	301	TGACTCAAGAGGGTTAAATTTCTGGTGCTGAAGCTGGGGCAGGGGTGTAAAGAAAACAC	360	PR	16-SEP-1998; 98WO-US019330.	PR
Db	301	TGACTCAAGAGGGTTAAATTTCTGGTGCTGAAGCTGGGGCAGGGGTGTAAAGAAAACAC	360	PR	17-SEP-1998; 98WO-US019437.	PR
QY	361	TTAGATTCATCATGTAAATTTAAGGCAATACACATATTAGTATACCTTAGTGTAT	420	PR	07-OCT-1998; 98WO-US021141.	PR
Db	361	TTAGATTCATCATGTAAATTTAAGGCAATACACATATTAGTATACCTTAGTGTAT	420	PR	29-OCT-1998; 98WO-US022991.	PR
QY	421	GTATCCCTGTCTATATACAAATAGGTGAAATTTAAAGTACCTATGCAAGTTGGCTGGAC	480	PR	29-OCT-1998; 98WO-US022992.	PR
Db	421	GTATCCCTGTCTATATACAAATAGGTGAAATTTAAAGTACCTATGCAAGTTGGCTGGAC	480	PR	20-NOV-1998; 98WO-US024855.	PR
QY	481	AGTTCTAAATGGACCTTTTAAATTTTAAATCAGTAATCATCTATGCTAGTGTAT	540	PR	01-DEC-1998; 98WO-US025108.	PR
Db	481	AGTTCTAAATGGACCTTTTAAATTTTAAATCAGTAATCATCTATGCTAGTGTAT	540	PR	05-JAN-1999; 99WO-US000106.	PR
QY	541	GCTTAGATCTACAGAGATCATATAATTTGATACAAATAAGAAAGGTCTCTCCCC	600	PR	08-MAR-1999; 99WO-US005028.	PR
Db	541	GCTTAGATCTACAGAGATCATATAATTTGATACAAATAAGAAAGGTCTCTCCCC	600	PR	10-MAR-1999; 99WO-US005190.	PR
QY	601	TTACAGAAATGCAATTTTAAATTCGAGATCAGTTAGAAATAGGAAATATGACATTAGAAAGG	660	PR	20-MAR-1999; 2000WO-US006319.	PR
Db	601	TTACAGAAATGCAATTTTAAATTCGAGATCAGTTAGAAATAGGAAATATGACATTAGAAAGG	660	PR	20-MAR-1999; 2000WO-US006319.	PR
QY	661	AGAATGACAGGAG	713	PR	20-APR-1999; 99WO-US008615.	PR
Db	661	AGAATGACAGGAG	713	PR	14-MAY-1999; 99WO-US010733.	PR

RESULT 202  
ADE89336  
ID ADE89336 standard; cDNA; 713 BP.  
AC ADE89336;  
DT 29-JAN-2004 (first entry)  
DE Human PRO polynucleotide #237.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
PX  
FN US2003199062-A1.  
XX  
PD 23-OCT-2003.  
XX

28-FEB-2001; 2001US-00796498.  
 PR 01-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen MF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2004-041360/04.  
 DR P-PSDB; ADE89337.  
 DR  
 XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or  
 PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
 PT attack, various coagulation disorders, tumors.  
 XX Claim 2; SEQ ID NO 473; 638pp; English.  
 PS  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 713 BP; 262 A; 105 C; 134 G; 212 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 713; DB 1; Length 713;  
 Best Local Similarity 100.0%; Pred. No. 1.4;  
 Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AATATATCATCTATTATCAATTAATCAATAAATGATTTCTTTTATCCCAATAACATTGGG 60  
 DB 1 AATATATCATCTATTATCAATTAATCAATAAATGATTTCTTTTATCCCAATAACATTGGG 60  
 QY 61 TTTTGGGATTTTAAATTTTCAAAACACAGCAGAAATGACATTTTCTGTCTACTATTATTAT 120  
 DB 61 TTTTGGGATTTTAAATTTTCAAAACACAGCAGAAATGACATTTTCTGTCTACTATTATTAT 120  
 QY 121 GTTGGTATGTGAAGCTATTGTGAGATCCAAATTCAGGAAGCAACACATTGGAGATGGCTA 180  
 DB 121 GTTGGTATGTGAAGCTATTGTGAGATCCAAATTCAGGAAGCAACACATTGGAGATGGCTA 180  
 QY 181 CTTTCTATCAAGAAATAPAGAGAACCCACAGTCAACCCACACATCATCTTTAGAAGACAG 240  
 DB 181 CTTTCTATCAAGAAATAPAGAGAACCCACAGTCAACCCACACATCATCTTTAGAAGACAG 240  
 QY 241 TGTGACTCCTCAACAAAGCTGTCAAAACACAGCAGGAGGCGATAGTTAAAGGACGGAATCT 300  
 DB 241 TGTGACTCCTCAACAAAGCTGTCAAAACACAGCAGGAGGCGATAGTTAAAGGACGGAATCT 300  
 QY 301 TGACTCAAGAGGGTTAAATTTCTGGTCTGAAGCTGGGCGAGGGGTAAAGAAAACAC 360  
 DB 301 TGACTCAAGAGGGTTAAATTTCTGGTCTGAAGCTGGGCGAGGGGTAAAGAAAACAC 360  
 QY 361 TTAGATTCAATGATTTGTAATTTTAAAGGCAAAATACATATTAGTATTACCTTAGTGTAA 420  
 DB 361 TTAGATTCAATGATTTGTAATTTTAAAGGCAAAATACATATTAGTATTACCTTAGTGTAA 420  
 QY 421 GTATCCTCTGCATATATACAAATTAAGTGAAATTAAGTACCCTATGCGAGTTGGCTGGAC 480  
 DB 421 GTATCCTCTGCATATATACAAATTAAGTGAAATTAAGTACCCTATGCGAGTTGGCTGGAC 480  
 QY 481 AGTCTCAATTTGACCTTTTAAATTTTAAATTCAGTAACTGATTTATCAGTGGCTATGT 540  
 DB 481 AGTCTCAATTTGACCTTTTAAATTTTAAATTCAGTAACTGATTTATCAGTGGCTATGT 540  
 QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAAATAAAGAAAGTGTTCCTCCCC 600  
 DB 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAAATAAAGAAAGTGTTCCTCCCC 600  
 QY 601 TTACAGAAATGACATTTTAAATTCGATACAGTTAGTAAATAGGAATATGACATTAGAAAG 660  
 DB 601 TTACAGAAATGACATTTTAAATTCGATACAGTTAGTAAATAGGAATATGACATTAGAAAG 660  
 QY 661 AAGAATCAGAGGAGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGG 713  
 DB 661 AAGAATCAGAGGAGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGG 713  
 RESULT 203  
 ADE18475  
 ID ADE18475 standard; cDNA; 713 BP.  
 XX  
 XX ADE18475;  
 AC  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 XX Human PRO polynucleotide #237.  
 XX  
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; kidney; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003194794-A1.  
 XX  
 PD 16-OCT-2003.  
 XX  
 PF 17-APR-2002; 2002US-00125805.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 10-MAR-1999; 2000WO-US006319.  
 PR 20-APR-1999; 99WO-US010733.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 28-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00806889.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828365.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-021079/02.

P-PSDB; ADE18476.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, for use in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; SEQ ID NO 473; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a

medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The reference data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX  
SQ Sequence 713 BP; 262 A; 105 C; 134 G; 212 T; 0 U; 0 Other;

Query Match		100.0%;	Score 713;	DB 1;	Length 713;
Best Local Similarity		100.0%;	Pred. No. 1.4;		
Matches 713;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	AATATATCATCTATTTATCATTAATCAATAGTATTTCTTTATTCATCAATACATTGGG	60		
Db	1	AATATATCATCTATTTATCATTAATCAATAGTATTTCTTTATTCATCAATACATTGGG	60		
QY	61	TTTGGGATTTTAAATTTTCAACACAGAGATGACATTTTCTGTCACTATTTATTT	120		
Db	61	TTTGGGATTTTAAATTTTCAACACAGAGATGACATTTTCTGTCACTATTTATTT	120		
QY	121	GTGGTATGTCAGCTATTTGGAGATCAATTCAGGAGCAACACATTTGGAGATGGCTA	180		
Db	121	GTGGTATGTCAGCTATTTGGAGATCAATTCAGGAGCAACACATTTGGAGATGGCTA	180		
QY	181	CTTTCTATCAAGAAATTAAGAGAACCCAGTCAACCCACACATCTTTTAGAAGACAG	240		
Db	181	CTTTCTATCAAGAAATTAAGAGAACCCAGTCAACCCACACATCTTTTAGAAGACAG	240		
QY	241	TGTGACTCTACAAAGCTGTCAAAACACAGGCAAGGCGTAGTTAAGACCGAATCT	300		
Db	241	TGTGACTCTACAAAGCTGTCAAAACACAGGCAAGGCGTAGTTAAGACCGAATCT	300		
QY	301	TGACTCAAGAGGGTTAATTTCTGTGCTGAAGCCTGGGGCAGGGGTGTAAGAAAAACAC	360		
Db	301	TGACTCAAGAGGGTTAATTTCTGTGCTGAAGCCTGGGGCAGGGGTGTAAGAAAAACAC	360		
QY	361	TTAGATTCATGATGTAAATTTAAGGCAATACACATATTAGTATTAACCTTAGTGTAT	420		
Db	361	TTAGATTCATGATGTAAATTTAAGGCAATACACATATTAGTATTAACCTTAGTGTAT	420		
QY	421	GTATCCCTGTATATATATCAATAGGTGAAATTAAGTACCTATGAGTTGGCTGGAC	480		
Db	421	GTATCCCTGTATATATATCAATAGGTGAAATTAAGTACCTATGAGTTGGCTGGAC	480		
QY	481	AGTTCTAAATGGACCTTTATTAATTTTAAATTCAGTAACCTATGATTTACCTGGCTATGT	540		
Db	481	AGTTCTAAATGGACCTTTATTAATTTTAAATTCAGTAACCTATGATTTACCTGGCTATGT	540		
QY	541	GCTTAGATCTACAGGAGATCATATATTTTGATACAAATTAAGAAATATGACATTAGAAAGG	600		
Db	541	GCTTAGATCTACAGGAGATCATATATTTTGATACAAATTAAGAAATATGACATTAGAAAGG	600		
QY	601	TTACAGAAATTCATTTTAAATGCGGATACAGTTAGTAATAGGAAATATGACATTAGAAAGG	660		
Db	601	TTACAGAAATTCATTTTAAATGCGGATACAGTTAGTAATAGGAAATATGACATTAGAAAGG	660		
QY	661	AGAATGACAGGAGAAAGGAAGGGAATGTTGCCAAGGAAAAA	713		
Db	661	AGAATGACAGGAGAAAGGAAGGGAATGTTGCCAAGGAAAAA	713		

RESULT 204	
AD888784	
ID	AD888784 standard; CDNA; 713 BP.
XX	
AC	AD888784;
XX	
DT	29-JAN-2004 (first entry)
XX	
DE	Human PRO polynucleotide #237.
XX	
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW	immune system cell infiltration.
XX	
OS	Homo sapiens.
XX	
PN	US2003199054-A1.
XX	
PD	23-OCT-2003.
XX	
PF	12-APR-2002; 2002US-00121054.
XX	
PR	31-MAR-1997; 97WO-US005230.
PR	12-JUN-1998; 98WO-US012456.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019094.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.
PR	29-OCT-1998; 98WO-US022991.
PR	29-OCT-1998; 98WO-US022992.
PR	20-NOV-1998; 98WO-US024855.
PR	01-DEC-1998; 98WO-US025108.
PR	05-JAN-1999; 99WO-US000106.
PR	08-MAR-1999; 99WO-US005190.
PR	10-MAR-1999; 2000WO-US006319.
PR	20-APR-1999; 99WO-US008615.
PR	14-MAY-1999; 99WO-US010733.
PR	02-JUN-1999; 99WO-US012252.
PR	01-SEP-1999; 99WO-US020111.
PR	08-SEP-1999; 99WO-US020594.
PR	13-SEP-1999; 99WO-US020944.
PR	15-SEP-1999; 99WO-US021090.
PR	15-SEP-1999; 99WO-US021547.
PR	05-OCT-1999; 99WO-US023089.
PR	29-NOV-1999; 99WO-US028214.
PR	30-NOV-1999; 99WO-US028313.
PR	30-NOV-1999; 99WO-US028409.
PR	01-DEC-1999; 99WO-US028301.
PR	01-DEC-1999; 99WO-US028634.
PR	01-DEC-1999; 99WO-US028851.
PR	02-DEC-1999; 99WO-US028854.
PR	02-DEC-1999; 99WO-US028855.
PR	16-DEC-1999; 99WO-US030095.
PR	20-DEC-1999; 99WO-US030911.
PR	20-DEC-1999; 99WO-US030999.
PR	22-DEC-1999; 99WO-US030720.
PR	30-DEC-1999; 99WO-US031243.
PR	30-DEC-1999; 99WO-US031274.
PR	05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US000365.  
 PR 18-FEB-2000; 2000WO-US000431.  
 PR 18-FEB-2000; 2000WO-US000432.  
 PR 22-FEB-2000; 2000WO-US000414.  
 PR 24-FEB-2000; 2000WO-US000414.  
 PR 24-FEB-2000; 2000WO-US000504.  
 PR 01-MAR-2000; 2000WO-US000501.  
 PR 02-MAR-2000; 2000WO-US000561.  
 PR 02-MAR-2000; 2000WO-US000584.  
 PR 15-MAR-2000; 2000WO-US000688.  
 PR 20-MAR-2000; 2000WO-US000737.  
 PR 31-MAR-2000; 2000WO-US000752.  
 PR 30-MAR-2000; 2000WO-US000843.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 28-JUN-2000; 2000WO-US015264.  
 PR 28-JUN-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023528.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 28-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2004-041356/04.  
 DR P-PSDB; ADS88785.  
 XX  
 DR  
 XX  
 PT Novel secreted and transmembrane polypeptides, PRO useful for treating  
 PT bone disorders, arthritis, heart attack, injuries, tumors, and  
 PT stimulating release of TNF-alpha from human blood.  
 XX  
 XX  
 PS Claim 2; SEQ ID NO 473; 638pp; English.  
 PS The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC anisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalasaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 713 BP; 262 A; 105 C; 134 G; 212 T; 0 U; 0 Other;  
 Query Match 100.0%; Score 713; DB 1; Length 713;  
 Best Local Similarity 100.0%; Pred. No. 1.4;  
 Matches 713; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 AATATATCATCTATTATATCAATTAATCAATATGATGATCTTTTATCCCAATTAACATTGGG 60  
 DB 1 AATATATCATCTATTATATCAATTAATCAATATGATGATCTTTTATCCCAATTAACATTGGG 60  
 QY 61 TTTTGGGATTTTAAATTTTCAAACACAGCAGAAATGACATTTTCTGTCACTATTATTATT 120  
 DB 61 TTTTGGGATTTTAAATTTTCAAACACAGCAGAAATGACATTTTCTGTCACTATTATTATT 120  
 QY 121 GTTGTATGTGAAGCTATTGTGAGATCCCAATTCAGGAGCAGACACATTCGAGAAATGGCTA 180  
 DB 121 GTTGTATGTGAAGCTATTGTGAGATCCCAATTCAGGAGCAGACACATTCGAGAAATGGCTA 180  
 QY 181 CTTTCTATCAAGAAATAAAGAGAACCCACAGTCAACCCACACATCATCTTTTGAAGACAG 240  
 DB 181 CTTTCTATCAAGAAATAAAGAGAACCCACAGTCAACCCACACATCATCTTTTGAAGACAG 240  
 QY 241 TGTGACTCCTACCAAGCTGTCAAACCCAGGCAAGGGCATAGTTAAAGGACGGAATCT 300  
 DB 241 TGTGACTCCTACCAAGCTGTCAAACCCAGGCAAGGGCATAGTTAAAGGACGGAATCT 300  
 QY 301 TGACTCAAGAGGTTAAATCTTGGTCTGAGCCCTGGGCGAGGGGTGTAAAGAAAACAC 360  
 DB 301 TGACTCAAGAGGTTAAATCTTGGTCTGAGCCCTGGGCGAGGGGTGTAAAGAAAACAC 360  
 QY 361 TTAGATTCAATGATTGTAATTTAAGGCAATATACATATTAGTATTACCTTAGTGTAAAT 420  
 DB 361 TTAGATTCAATGATTGTAATTTAAGGCAATATACATATTAGTATTACCTTAGTGTAAAT 420  
 QY 421 GTATCCCTGTCTATATATCAATTAAGGTGAATTAAGTACCTTACCTTAGTGTGGTGCAC 480  
 DB 421 GTATCCCTGTCTATATATCAATTAAGGTGAATTAAGTACCTTACCTTAGTGTGGTGCAC 480  
 QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATTAAGTAACTAGTAACTATATACCTAGCTATGT 540

```
Db 481 AGTCTAAATGGACTTTTATTAATTTTAAATCAGTAACAGTGAATTAATCACTGGCTATGT 540
QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAGAAAGTGTCTCTCCCC 600
Db 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATAAGAAAGTGTCTCTCCCC 600
QY 601 TTACAGAATTGACATTTTAAATCGGATACACAGTTAGAAATATGACATTAGAAAG 660
Db 601 TTACAGAATTGACATTTTAAATCGGATACACAGTTAGAAATATGACATTAGAAAG 660
QY 661 AAGAATGACAGGAGAGAAAGAAAGGAAATGTTGCCAAGGAAAAAAA 713
Db 661 AAGAATGACAGGAGAGAAAGAAAGGAAATGTTGCCAAGGAAAAAAA 713

RESULT 205
AAK81282/c
ID AAK81282 standard; DNA; 5709 BP.
XX
AC AAK81282;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:36094.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001354.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214896P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0217496P.
PR 26-JUL-2000; 2000US-0218290P.
PR 14-AUG-2000; 2000US-0220963P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239353P.
PR 13-OCT-2000; 2000US-0239377P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
```



PR 17-NOV-2000; 2000US-0249213P.  
 PR 17-NOV-2000; 2000US-0249214P.  
 PR 17-NOV-2000; 2000US-0249215P.  
 PR 17-NOV-2000; 2000US-0249216P.  
 PR 17-NOV-2000; 2000US-0249217P.  
 PR 17-NOV-2000; 2000US-0249218P.  
 PR 17-NOV-2000; 2000US-0249244P.  
 PR 17-NOV-2000; 2000US-0249245P.  
 PR 17-NOV-2000; 2000US-0249264P.  
 PR 17-NOV-2000; 2000US-0249265P.  
 PR 17-NOV-2000; 2000US-0249297P.  
 PR 17-NOV-2000; 2000US-0249299P.  
 PR 17-NOV-2000; 2000US-0249300P.  
 PR 01-DEC-2000; 2000US-0250160P.  
 PR 01-DEC-2000; 2000US-0250391P.  
 PR 05-DEC-2000; 2000US-0251030P.  
 PR 05-DEC-2000; 2000US-0251988P.  
 PR 05-DEC-2000; 2000US-0256719P.  
 PR 06-DEC-2000; 2000US-0251479P.  
 PR 08-DEC-2000; 2000US-0251856P.  
 PR 08-DEC-2000; 2000US-0251868P.  
 PR 08-DEC-2000; 2000US-0251869P.  
 PR 08-DEC-2000; 2000US-0251989P.  
 PR 08-DEC-2000; 2000US-0251990P.  
 PR 11-DEC-2000; 2000US-0254097P.  
 PR 05-JAN-2001; 2001US-0259678P.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Rosen CA, Barash SC, Ruben SM;  
 XX WPI; 2001-483426/52.  
 DR  
 XX  
 XX Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
 PT useful for preventing, diagnosing and/or treating cancers and metastasis.  
 PT  
 XX  
 XX Disclosure; SEQ ID NO 36094; 3071pp + Sequence Listing; English.  
 PS  
 XX  
 CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)  
 CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic  
 CC activity, and can be used in gene therapy and vaccine production. (I)  
 CC proteins and polynucleotides may be used in the prevention, diagnosis and  
 CC treatment of diseases associated with inappropriate (I) expression. For  
 CC example, they may be used to treat disorders associated with decreased  
 CC expression by rectifying mutations or deletions in a patient's genome  
 CC that affect the activity of (I) by expressing inactive proteins or to  
 CC supplement the patients own production of (I). Additionally, (I)  
 CC polynucleotides may be used to produce the secreted (I), by inserting the  
 CC nucleic acids into a host cell and culturing the cell to express the  
 CC protein. (I) proteins and polynucleotides may be used to prevent,  
 CC diagnose and treat immune/hematopoietic-related diseases, especially  
 CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703  
 CC to AAK87694 represent human immune/hematopoietic antigen genomic  
 CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169  
 CC represent sequences used in the exemplification of the present invention  
 CC  
 XX  
 XX Sequence 5709 BP; 1849 A; 1109 C; 988 G; 1763 T; 0 U; 0 Other;  
 SQ  
 Query Match 99.0%; Score 705.6; DB 1; Length 5709;  
 Best Local Similarity 99.4%; Pred. No. 0.19;  
 Matches 708; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 AATATATCATCTATTATCATTAATCAATATGATTTCTTTTATCCAAATACATTTGGG 60  
 DB 2310 AATATATCATCTATTATCATTAATCAATATGATTTCTTTTATCCAAATACATTTGGG 2251  
 QY 61 TTTTGGGATTTTAAATTTCAACACAGCAGATGACATTTTCTGTCACATTTATTTATT 120  
 DB 2250 TTTTGGGATTTTAAATTTCAACACAGCAGATGACATTTTCTGTCACATTTATTTATT 2191  
 QY 121 GTTGTGTGTAAGCTATTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGGCTA 180  
 DB 2190 GTTGTGTGTAAGCTATTTGGAGATCCAAATTCAGGAGCAACACATTTGGAGATGGCTA 2131

QY 181 CTTTCTATCAAGAAATAAGAGAACCAAGTCAAGCCACACAAATCATCTTTAGAGACAG 240  
 DB 2130 CTTTCTATCAAGAAATAAGAGAACCAAGTCAAGCCACACAAATCATCTTTAGAGACAG 2071  
 QY 241 TGTGACTCCTACCAAGCTGTCAAAACACACAGGCAAGGTCATAGTTTAAAGGACGGATCT 300  
 DB 2070 TGTGACTCCTACCAAGCTGTCAAAACACACAGGCAAGGTCATAGTTTAAAGGACGGATCT 2011  
 QY 301 TGACTCAAGAGGGTTAAATTCITGGTGCTGGAAGCCTGGGGCAGGGGTGTAAAGAAAACAC 360  
 DB 2010 TGACTCAAGAGGGTTAAATTCITGGTGCTGGAAGCCTGGGGCAGGGGTGTAAAGAAAACAC 1951  
 QY 361 TTAGATTCAATGATTTGTAATTTAAGGCAATACACATATTAGTATTAATCTTAGTGTAA 420  
 DB 1950 TTAGATTCAATGATTTGTAATTTAAGGCAATACACATATTAGTATTAATCTTAGTGTAA 1891  
 QY 421 GTATCCCTGCTATATACATAAAGGTGAAATTTATAAGTACCCCTATGCAGTTGGCTGGAC 480  
 DB 1890 GTATCCCTGCTATATACATAAAGGTGAAATTTATAAGTACCCCTATGCAGTTGGCTGGAC 1831  
 QY 481 AGTTCTAAATTTGGACTTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTT 540  
 DB 1830 AGTTCTAAATTTGGACTTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTT 1771  
 QY 541 GCTTAGATCTACAGGAGATCATATAATTTTGTATACAAATTAAGAAAGAGTGTCTCTCCCC 600  
 DB 1770 GCTTAGATCTACAGGAGATCATATAATTTTGTATACAAATTAAGAAAGAGTGTCTCTCCCC 1711  
 QY 601 TTACAGATTGACATTTTAAATTCGGATACAGTTAGAAATAGGAAATATGACATTAGAAAGG 660  
 DB 1710 TTACAGATTGACATTTTAAATTCGGATACAGTTAGAAATAGGAAATATGACATTAGAAAGG 1651  
 QY 661 AAGAATGACAGGAGAGAAAGAAAGAGGAAATTTGCCAAGGAAAAA 712  
 DB 1650 AAGAATGACAGGAGAGAAAGAAAGAGGAAATTTGCCAAGGAAAAA 1599  
 RESULT 206  
 AAC91481  
 ID AAC91481 standard; cDNA; 712 BP.  
 XX  
 AC AAC91481;  
 XX  
 DT 21-MAR-2001 (first entry)  
 XX  
 DE Human PRO1159 cDNA.  
 XX  
 KW Human; PRO; antiinflammatory; dermatological; antiarthritic;  
 KW antirheumatic; cardiant; antianaemic; immunosuppressive; antithyroid;  
 KW antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;  
 KW antiallergic; antiasthmatic; immune related disorder;  
 KW hepatobiliary disease; autoimmune disease; allergy; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200073452-A2.  
 XX  
 PD 07-DEC-2000.  
 XX  
 PF 02-JUN-2000; 2000WO-US015264.  
 XX  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 20-JUL-1999; 99US-0144732P.  
 PR 20-JUL-1999; 99US-0144758P.  
 PR 28-JUL-1999; 99US-0146222P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 29-OCT-1999; 99US-0162506P.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028565.  
 PR 09-DEC-1999; 99US-0170262P.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 03-MAR-2000; 2000US-0187202P.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.

(GETH ) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Chan B, Goddard A, Godowski PJ;  
 PI Gurney AL, Hebert C, Henzel W, Kabakoff RC, Shelton DL, Tumas D;  
 PI Watanabe CK, Wood WI;

XX WPI; 2001-025253/03.  
 DR P-PSDB; AAB50922.

XX Thirty three nucleic acids encoding PRO polypeptides which are useful in  
 XX the diagnosis and treatment of immune related disorders, e.g. systemic  
 XX lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis  
 XX and diabetes mellitus.

XX Claim 48; Fig 41; 218pp; English.

XX The present sequence is one of thirty three nucleic acids encoding PRO  
 CC polypeptides. The PRO polypeptides, anti-PRO antibodies, agonists and  
 CC antagonists are useful for treating and diagnosing immune related  
 CC disorders such as systemic lupus erythematosus, rheumatoid arthritis,  
 CC osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,  
 CC systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's  
 CC syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic  
 CC anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus,  
 CC immune-mediated renal disease, demyelinating diseases of the central and  
 CC peripheral nervous systems (such as multiple sclerosis, idiopathic  
 CC demyelinating polyneuropathy or Guillain-Barre syndrome, and chronic  
 CC inflammatory demyelinating polyneuropathy), hepatobiliary diseases (such  
 CC as infectious, autoimmune chronic active hepatitis, primary biliary  
 CC cirrhosis, granulomatous hepatitis and sclerosing cholangitis),  
 CC inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's  
 CC disease, autoimmune or immune-mediated skin diseases (such as bullous  
 CC skin diseases, erythema multiforme, contact dermatitis, psoriasis),  
 CC allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,  
 CC food hypersensitivity and urticaria), immunological diseases of the lung  
 CC (such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and  
 CC hypersensitivity pneumonitis), transplantation associated diseases  
 CC including graft rejection and graft-versus-host diseases

XX Sequence 712 BP; 262 A; 105 C; 134 G; 211 T; 0 U; 0 Other;

XX Query Match 98.4%; Score 701.5; DB 1; Length 712;  
 XX Best Local Similarity 99.9%; Pred. No. 1.6;  
 XX Matches 712; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 AATATATCATCTTTTATCATTAATCAATTAATGTTATTTTATTTTCAATTAACATTGGG 60  
 DB 1 AATATATCATCTTTTATCATTAATCAATTAATGTTATTTTATTTTCAATTAACATTGGG 60  
 QY 61 TTTTGGGATTTTAAATTTTCAAAACACAGCAGAAATGACATTTTCTGTCACTATTATT 120  
 DB 61 TTTTGGGATTTTAAATTTTCAAAACACAGCAGAAATGACATTTTCTGTCACTATTATT 120

QY 121 GTTGGTATGTGAAGCTATTATTGGAGATCCAAATTCAGGAAGCAACACATTGGAGATGGCTA 180  
 DB 121 GTTGGTATGTGAAGCTATTATTGGAGATCCAAATTCAGGAAGCAACACATTGGAGATGGCTA 180  
 QY 181 CTTTCTATCAAGAAATTAAGAGAACACACAGTCAACCCACACAAATCATCTTTAGAGACAG 240  
 DB 181 CTTTCTATCAAGAAATTAAGAGAACACACAGTCAACCCACACAAATCATCTTTAGAGACAG 240  
 QY 241 TGTGACTCTCTACCAAGAGCTGTCAAAACCCACAGCAAGGGCATAGTTAAAGAGCGGAATCT 300  
 DB 241 TGTGACTCTCTACCAAGAGCTGTCAAAACCCACAGCAAGGGCATAGTTAAAGAGCGGAATCT 300  
 QY 301 TGACTCAAGAGGGTTAATTTCTTGGTCTGAAGCCTGGGGCAGGGGTGTAAGAAACAC 360  
 DB 301 TGACTCAAGAGGGTTAATTTCTTGGTCTGAAGCCTGGGGCAGGGGTGTAAGAAACAC 360  
 QY 361 TTGATTTCAATGATTGTAAATTTTAAAGGCAATATACATATTAGTATTACCTTAGTGTAAAT 420  
 DB 361 TTGATTTCAATGATTGTAAATTTTAAAGGCAATATACATATTAGTATTACCTTAGTGTAAAT 420  
 QY 421 GTATCCCTGTCTATATATACAAATTAAGGTGAATATATAAGTACCCCTATGAGTTGGCTGGAC 480  
 DB 421 GTATCCCTGTCTATATATACAAATTAAGGTGAATATATAAGTACCCCTATGAGTTGGCTGGAC 480  
 QY 481 AGTTCTAAATTTGAGCTTTTATTAATTTTAAATCAGTAACTGATTTTATCTAGTGTATGT 540  
 DB 481 AGTTCTAAATTTGAGCTTTTATTAATTTTAAATCAGTAACTGATTTTATCTAGTGTATGT 540  
 QY 541 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATTAAGAAAGAGTGTCTCTCCCC 600  
 DB 540 GCTTAGATCTACAGGAGATCATATAATTTGATACAAATTAAGAAAGAGTGTCTCTCCCC 599  
 QY 601 TTACAGAAATTTGACATTTTAAATGGATACAGTTAGAAATAGGAATATGACATTAGAAAGG 660  
 DB 600 TTACAGAAATTTGACATTTTAAATGGATACAGTTAGAAATAGGAATATGACATTAGAAAGG 659  
 QY 661 AAGATGACAGGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAG 713  
 DB 660 AAGATGACAGGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAG 712

RESULT 207

AAK81284/C  
 ID AAK81284 standard; DNA; 336 BP.

XX  
 AC AAK81284;

XX 07-NOV-2001 (first entry)

XX Human immune/haematopoietic antigen genomic sequence SEQ ID NO:36096.

XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;  
 XX cytostatic; gene therapy; vaccine; metastasis; ds.

XX Homo sapiens.

XX WO200157182-A2.

XX 09-AUG-2001.

XX 17-JAN-2001; 2001WO-US001354.

XX 31-JAN-2000; 2000US-0179065P.

XX 04-FEB-2000; 2000US-0180628P.

XX 24-FEB-2000; 2000US-0184664P.

XX 02-MAR-2000; 2000US-0186350P.

XX 16-MAR-2000; 2000US-0189874P.

XX 17-MAR-2000; 2000US-0190076P.

XX 18-APR-2000; 2000US-0198123P.

XX 19-MAY-2000; 2000US-0205515P.

XX 07-JUN-2000; 2000US-0209467P.

XX 28-JUN-2000; 2000US-0214886P.

PR 30-JUN-2000; 2000US-0215135P.  
 PR 07-JUL-2000; 2000US-0216647P.  
 PR 07-JUL-2000; 2000US-0216880P.  
 PR 11-JUL-2000; 2000US-0217487P.  
 PR 11-JUL-2000; 2000US-0217496P.  
 PR 14-JUL-2000; 2000US-0218290P.  
 PR 26-JUL-2000; 2000US-0220963P.  
 PR 26-JUL-2000; 2000US-0220964P.  
 PR 14-AUG-2000; 2000US-0224518P.  
 PR 14-AUG-2000; 2000US-0224519P.  
 PR 14-AUG-2000; 2000US-0225213P.  
 PR 14-AUG-2000; 2000US-0225214P.  
 PR 14-AUG-2000; 2000US-0225266P.  
 PR 14-AUG-2000; 2000US-0225267P.  
 PR 14-AUG-2000; 2000US-0225268P.  
 PR 14-AUG-2000; 2000US-0225270P.  
 PR 14-AUG-2000; 2000US-0225447P.  
 PR 14-AUG-2000; 2000US-0225575P.  
 PR 14-AUG-2000; 2000US-0225758P.  
 PR 14-AUG-2000; 2000US-0225759P.  
 PR 18-AUG-2000; 2000US-0226279P.  
 PR 22-AUG-2000; 2000US-0226681P.  
 PR 22-AUG-2000; 2000US-0226868P.  
 PR 22-AUG-2000; 2000US-0227182P.  
 PR 23-AUG-2000; 2000US-0227009P.  
 PR 30-AUG-2000; 2000US-0228924P.  
 PR 01-SEP-2000; 2000US-0229343P.  
 PR 01-SEP-2000; 2000US-0229344P.  
 PR 01-SEP-2000; 2000US-0229345P.  
 PR 05-SEP-2000; 2000US-0229509P.  
 PR 05-SEP-2000; 2000US-0229513P.  
 PR 06-SEP-2000; 2000US-0230437P.  
 PR 06-SEP-2000; 2000US-0230438P.  
 PR 08-SEP-2000; 2000US-0231242P.  
 PR 08-SEP-2000; 2000US-0231243P.  
 PR 08-SEP-2000; 2000US-0231244P.  
 PR 08-SEP-2000; 2000US-0231413P.  
 PR 08-SEP-2000; 2000US-0231414P.  
 PR 08-SEP-2000; 2000US-0232080P.  
 PR 08-SEP-2000; 2000US-0232081P.  
 PR 12-SEP-2000; 2000US-0231968P.  
 PR 14-SEP-2000; 2000US-0232397P.  
 PR 14-SEP-2000; 2000US-0232398P.  
 PR 14-SEP-2000; 2000US-0232399P.  
 PR 14-SEP-2000; 2000US-0232400P.  
 PR 14-SEP-2000; 2000US-0232401P.  
 PR 14-SEP-2000; 2000US-0233083P.  
 PR 14-SEP-2000; 2000US-0233084P.  
 PR 14-SEP-2000; 2000US-0233065P.  
 PR 21-SEP-2000; 2000US-0234223P.  
 PR 21-SEP-2000; 2000US-0234274P.  
 PR 25-SEP-2000; 2000US-0234957P.  
 PR 25-SEP-2000; 2000US-0234958P.  
 PR 26-SEP-2000; 2000US-0235484P.  
 PR 27-SEP-2000; 2000US-0235834P.  
 PR 27-SEP-2000; 2000US-0235836P.  
 PR 29-SEP-2000; 2000US-0236327P.  
 PR 29-SEP-2000; 2000US-0236367P.  
 PR 29-SEP-2000; 2000US-0236368P.  
 PR 29-SEP-2000; 2000US-0236369P.  
 PR 29-SEP-2000; 2000US-0236370P.  
 PR 02-OCT-2000; 2000US-0236802P.  
 PR 02-OCT-2000; 2000US-0237037P.  
 PR 02-OCT-2000; 2000US-0237038P.  
 PR 02-OCT-2000; 2000US-0237039P.  
 PR 02-OCT-2000; 2000US-0237040P.  
 PR 13-OCT-2000; 2000US-0239935P.  
 PR 13-OCT-2000; 2000US-0239937P.  
 PR 20-OCT-2000; 2000US-0240960P.  
 PR 20-OCT-2000; 2000US-0241221P.  
 PR 20-OCT-2000; 2000US-0241785P.  
 PR 20-OCT-2000; 2000US-0241786P.

PR 20-OCT-2000; 2000US-0241787P.  
 PR 20-OCT-2000; 2000US-0241808P.  
 PR 20-OCT-2000; 2000US-0241809P.  
 PR 20-OCT-2000; 2000US-0241826P.  
 PR 01-NOV-2000; 2000US-0244617P.  
 PR 08-NOV-2000; 2000US-0246474P.  
 PR 08-NOV-2000; 2000US-0246475P.  
 PR 08-NOV-2000; 2000US-0246476P.  
 PR 08-NOV-2000; 2000US-0246477P.  
 PR 08-NOV-2000; 2000US-0246478P.  
 PR 08-NOV-2000; 2000US-0246523P.  
 PR 08-NOV-2000; 2000US-0248524P.  
 PR 08-NOV-2000; 2000US-0248525P.  
 PR 08-NOV-2000; 2000US-0248526P.  
 PR 08-NOV-2000; 2000US-0248527P.  
 PR 08-NOV-2000; 2000US-0248528P.  
 PR 08-NOV-2000; 2000US-0248532P.  
 PR 08-NOV-2000; 2000US-0248609P.  
 PR 08-NOV-2000; 2000US-0248610P.  
 PR 08-NOV-2000; 2000US-0248611P.  
 PR 08-NOV-2000; 2000US-0248613P.  
 PR 17-NOV-2000; 2000US-0249207P.  
 PR 17-NOV-2000; 2000US-0249208P.  
 PR 17-NOV-2000; 2000US-0249209P.  
 PR 17-NOV-2000; 2000US-0249210P.  
 PR 17-NOV-2000; 2000US-0249211P.  
 PR 17-NOV-2000; 2000US-0249212P.  
 PR 17-NOV-2000; 2000US-0249213P.  
 PR 17-NOV-2000; 2000US-0249214P.  
 PR 17-NOV-2000; 2000US-0249215P.  
 PR 17-NOV-2000; 2000US-0249216P.  
 PR 17-NOV-2000; 2000US-0249217P.  
 PR 17-NOV-2000; 2000US-0249218P.  
 PR 17-NOV-2000; 2000US-0249244P.  
 PR 17-NOV-2000; 2000US-0249245P.  
 PR 17-NOV-2000; 2000US-0249264P.  
 PR 17-NOV-2000; 2000US-0249265P.  
 PR 17-NOV-2000; 2000US-0249297P.  
 PR 17-NOV-2000; 2000US-0249299P.  
 PR 17-NOV-2000; 2000US-0249300P.  
 PR 01-DEC-2000; 2000US-0250391P.  
 PR 05-DEC-2000; 2000US-0251030P.  
 PR 05-DEC-2000; 2000US-0251988P.  
 PR 06-DEC-2000; 2000US-0251719P.  
 PR 06-DEC-2000; 2000US-0251792P.  
 PR 08-DEC-2000; 2000US-0251856P.  
 PR 08-DEC-2000; 2000US-0251868P.  
 PR 08-DEC-2000; 2000US-0251869P.  
 PR 08-DEC-2000; 2000US-0251989P.  
 PR 08-DEC-2000; 2000US-0251990P.  
 PR 11-DEC-2000; 2000US-0254097P.  
 PR 05-JAN-2001; 2001US-02559678P.  
 (HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-483426/52.

Nucleic acids encoding human immune/hematopoietic antigen polypeptides, useful for preventing, diagnosing and/or treating cancers and metastasis.

Disclosure; SEQ ID NO 36096; 3071pp + Sequence Listing; English.

AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I) amino acid sequences given in AAK82170 to AAK91921. (I) have cytostatic activity, and can be used in gene therapy and vaccine production. (I) proteins and polynucleotides may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate (I) expression. For example, they may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of (I) by expressing inactive proteins or to

CC supplement the patients own production of (I). Additionally, (I)  
 CC polynucleotides may be used to produce the secreted (I), by inserting the  
 CC nucleic acids into a host cell and culturing the cell to express the  
 CC protein. (I) proteins and polynucleotides may be used to prevent,  
 CC diagnose and treat immune/haematopoietic-related diseases, especially  
 CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703  
 CC to AAK87694 represent human immune/haematopoietic antigen genomic  
 CC sequences from the present invention. AAK54942 to AAK54950 and AAK82169  
 CC represent sequences used in the exemplification of the present invention  
 XX  
 SQ Sequence 336 BP; 98 A; 66 C; 49 G; 123 T; 0 U; 0 Other;

Query Match 46.7%; Score 332.8; DB 1; Length 336;  
 Best Local Similarity 99.4%; Pred. No. 98;  
 Matches 334; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 252 CCAAGCTGTCAAACACACAGGCAAGGCATAGTTAAAGGACGGAACTCTGACTCAAGAG 311  
 Db |||||||  
 QY 312 GGTAAATCTTGGTCTGAAGCTGGGCGAGGGGTAAAGAAACACCTTAGATTCAAT 371  
 Db |||||||  
 QY 276 GGTAAATCTTGGTCTGAAGCTGGGCGAGGGGTAAAGAAACACCTTAGATTCAAT 217  
 Db |||||||  
 QY 372 GATTGTAATTTAAGGCAAAATACACATATTAGTATTACCTTAGTGTATGTATCCCTGTC 431  
 Db |||||||  
 QY 432 ATATATACATTAAGTGAAATTTAAGTACCTATGAGTGGCTGGACAGTTCTAAAT 491  
 Db |||||||  
 QY 156 ATATATACATTAAGTGAAATTTAAGTACCTATGAGTGGCTGGACAGTTCTAAAT 97  
 Db |||||||  
 QY 492 GGACTTTTATTTTAAATCAGTAACTGATTTATCACTGGCTATGTGCTTAGATCTA 551  
 Db |||||||  
 QY 96 GGACTTTTATTTTAAATCAGTAACTGATTTATCACTGGCTATGTGCTTAGATCTA 37  
 Db |||||||  
 QY 552 CAGGAGATCATATAATTTGATCAAAATAAGAAAA 587  
 Db |||||||  
 QY 36 CAGGAGATCATATAATTTGATCAAAATAAGAAAA 1  
 Db |||||||

Search completed: June 2, 2004, 16:30:22  
 Job time : 75 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 29, 2004, 09:11:03 ; Search time 102 Seconds  
(without alignments)  
3879.216 Million cell updates/sec

Title: US-09-989-293A-376  
Perfect score: 713  
Sequence: 1 aatatcatcatattatca.....tggtgccaaggaaaaaaa 713

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 6500 summaries

Database : Issued Patents NA:  
1: /cgn2\_6/prodata/2/ina/5A\_COMB.seq:  
2: /cgn2\_6/prodata/2/ina/5B\_COMB.seq:  
3: /cgn2\_6/prodata/2/ina/6A\_COMB.seq:  
4: /cgn2\_6/prodata/2/ina/6B\_COMB.seq:  
5: /cgn2\_6/prodata/2/ina/PCTUS\_COMB.seq:  
6: /cgn2\_6/prodata/2/ina/backfiles1.seq:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	77.6	10.9	2298	3	US-08-772-440-1
2	75.2	10.5	528	3	US-08-772-440-7
3	46.6	6.5	7218	1	US-08-232-463-14
4	45.2	6.3	832	4	US-09-621-976-2813
5	44	6.2	640681	4	US-09-790-988-1
6	40.4	5.7	5847	4	US-09-920-672-10
7	39.6	5.6	20674	4	US-09-641-638-651
8	39.2	5.5	8920	2	US-08-446-855A-1
9	39.2	5.4	4526	1	US-07-855-412B-4
10	38.6	5.4	4526	2	US-08-308-887A-4
11	38.6	5.4	4526	3	US-08-881-094-4
12	38.6	5.4	58407	4	US-08-916-421B-2
13	38.4	5.4	19233	4	US-10-204-708-45
14	38	5.3	1537	4	US-09-626-959D-2
15	37.8	5.3	1537	4	US-09-734-674-3
16	37.8	5.3	202001	4	US-09-543-681A-1450
17	37.6	5.2	1335	4	US-08-585-593A-42
18	37.4	5.2	275	4	US-09-018-584A-9
19	37.4	5.2	361	3	US-07-867-106-5
20	37.4	5.2	2422	1	US-07-867-106-2
21	37.4	5.2	5852	1	US-07-867-106-2
22	37.4	5.2	786431	4	US-09-751-389-3
23	37.2	5.2	832	4	US-09-621-976-2813
24	37.2	5.2	9064	4	US-08-961-527-17
25	37	5.2	2110	3	US-09-419-459-1
26	37	5.2	10160	4	US-09-097-319A-8
27	37	5.2	10323	4	US-09-280-428A-11

C 28	37	5.2	11784	4	US-09-097-319A-9	Sequence 9, Appli
C 29	37	5.2	11991	4	US-09-097-319A-10	Sequence 10, Appli
C 30	37	5.2	24595	6	5428147-1	Patent No. 5428147
C 31	36.8	5.2	10467	4	US-10-204-708-2	Sequence 2, Appli
C 32	36.8	5.2	19124	2	US-08-487-826B-13	Sequence 13, Appli
C 33	36.6	5.1	10640	4	US-09-417-485D-5	Sequence 5, Appli
C 34	36.6	5.1	11131	4	US-10-204-708-27	Sequence 27, Appli
C 35	36.6	5.1	51952	3	US-08-947-823-1	Sequence 1, Appli
C 36	36.4	5.1	408	4	US-09-134-001C-1464	Sequence 1464, Ap
C 37	36.4	5.1	1946	4	US-09-886-319A-83	Sequence 83, Appli
C 38	36.4	5.1	3331	3	US-09-042-785A-1	Sequence 1, Appli
C 39	36.4	5.1	161652	4	US-09-497-855A-40	Sequence 40, Appli
C 40	36.2	5.1	6113	4	US-10-204-708-14	Sequence 14, Appli
C 41	36	5.0	6317	4	US-10-204-708-11	Sequence 11, Appli
C 42	36	5.0	11050	4	US-10-204-708-86	Sequence 86, Appli
C 43	36	5.0	50000	4	US-09-146-053-3	Sequence 3, Appli
C 44	35.8	5.0	1634	4	US-09-220-132-111	Sequence 111, App
C 45	35.8	5.0	2570	2	US-09-056-075-2	Sequence 2, Appli

Search completed: May 29, 2004, 11:16:47  
Job time : 1280 secs